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8ABSTRACT
Background—Beyond cholesterol, oxidative modification of LDL and small dense LDL
particles have also been related to the pathogenesis of atherosclerosis. The present studies aimed
to examine the interrelationships between LDL size and susceptibility of LDL to oxidation in
vitro after a marathon run (Study I) and in type 2 diabetes (Study II) or familial combined
hyperlipidemia (FCHL, Studies III and IV), known to influence oxidative stress and/or to be
associated with excess atherosclerosis. In addition, associations were investigated between HDL-
bound paraoxonase-1 (PON1) and in vitro HDL oxidation parameters in FCHL family members
(Study V). 
Subjects and methods—LDL peak particle diameter, susceptibility of LDL to oxidation in vitro,
and circulating antioxidants were measured in the study subjects: 11 marathon runners and 10
untrained controls (I), 30 type 2 diabetic patients and 12 normal controls (II), 256 FCHL family
members (III and IV), and 30 healthy spouse controls (III). In addition, we measured endothelial
function in 30 type 2 diabetic patients and 12 normal controls (II), and carotid IMT in 148 FCHL
family members (IV). In Study V, we measured serum PON1 and HDL oxidation in vitro in 150
FCHL family members.
Results—A single bout of aerobic endurance exercise increased plasma TRAP and the
susceptibility of LDL to oxidation in vitro, but not the LDL peak particle diameter or lipid-
soluble antioxidants in LDL. Patients with type 2 diabetes had a defect in endothelium-
dependent vasodilation and this defect correlated with reduction in LDL peak particle diameter,
but not with lag time for LDL oxidation. LDL particles from FCHL patients with different lipid
phenotypes were susceptible to oxidation and these changes may be attributed to the abundance
of small dense LDL particles in FCHL. LDL particle size, but not lag time for LDL oxidation,
was an independent determinant of carotid mean IMT in asymptomatic FCHL family members.
In Study V, PON1 mass was significantly associated with maximal dienes and with propagation
rate of HDL oxidation in vitro in FCHL family members. 
Conclusions—Acute aerobic endurance exercise may increase susceptibility of LDL to oxidation
in vitro that may be harmful for the health of the runner. The present studies demonstrated that
LDL particle size seems to be a more important risk factor in the development of preclinical
atherosclerosis than is the susceptibility of LDL to oxidation in vitro in type 2 diabetic patients
and FCHL family members free of cardiovascular disease. The presence of PON1 mass in HDL
is important in protecting HDL itself from in vitro oxidation in FCHL family members.  
91. INTRODUCTION
Numerous studies have shown that elevated serum low-density lipoprotein (LDL) cholesterol is
the crucial factor for the initiation and progression of atherosclerosis, and lowering LDL
cholesterol can largely reduce the incidence and mortality of cardio- and cerebro-vascular
diseases [1-3]. However, there is great variability in the incidence of coronary artery disease
(CAD) at any given level of plasma LDL cholesterol [4]. It is therefore important to define other
risk factors, which influence both the development of atherosclerosis and the response to
therapy, beyond the LDL cholesterol concentration [5]. In recent years, evidence has
accumulated that a number of cardiovascular risk factors other than traditional risk factors may
contribute to the development of atherosclerosis [6,7]. Among these novel risk factors, LDL
oxidation and LDL particle size have received extensive attention for their atherogenic potentials
since the last decade [5,8].  
Substantial evidence indicates that oxidized LDL is present in vivo within the atherosclerotic
lesion but not in the normal arterial wall [4,9]. Oxidized LDL can be recognized by the
scavenger receptors of the macrophages and induce subendothelial lipid accumulation and foam
cell formation, which are the earliest hallmarks of atherosclerosis [5]. The susceptibility of LDL
to oxidation in vitro was reported to be associated with CAD in a small-scale study [10], but was
only marginally associated with the extent of coronary atherosclerosis in a larger-scale clinical
study [11]. Observational studies demonstrate that higher blood concentrations or intakes of
antioxidant vitamins are associated with a reduced risk for CAD or stroke [12-16]. In animal
models, administration of lipid-soluble antioxidants can inhibit atherogenesis during
hypercholesterolemia [4,17]. Administration of antioxidant vitamins has, however, no effect on
the incidence and mortality of CAD in large-scale clinical trials [18-20]. 
LDL particles are heterogeneous with varying density, size, charge, and composition. Small
dense LDL particles are especially atherogenic and have been linked to increased risk for CAD
[8]. These particles penetrate the arterial wall more easily, and readily bind with intimal
proteoglycans [21], which may further increase the susceptibility of the lipoprotein to oxidation
[22]. Several clinical studies have shown that small dense LDL is indeed associated with an
increased risk for the development of CAD [8,23,24]. Zambon et al reported that a regression in
coronary artery stenosis with lipid-lowering drugs is independently related to the change in LDL
density [25]. Small dense LDL particles, however, often coexist with hypertriglyceridemia and
low level of HDL, and each one may be atherogenic. It is therefore difficult to dissect out their
relative contribution to atherogenesis [26]. LDL particle size may thus merely be a marker of
other lipid abnormalities [27].
During the past decade, susceptibility of LDL to oxidation, as an in vitro measure of LDL
oxidation, and LDL peak particle diameter, as a measure of LDL particle size, have been widely
examined in populations, and the strength of their association with cardiovascular events and
responsiveness to lifestyle modification have also been evaluated. In this thesis, the marathon
run served as an extreme model to test the effect of a single bout of exercise on these two
measures. To clarify the contribution of LDL oxidation vs small dense LDL to the development
of early atherosclerosis, we studied the associations between these measures and endothelial
dysfunction in asymptomatic patients with type 2 diabetes, and carotid intima-media thickness in
asymptomatic patients with familial combined hyperlipidemia (FCHL). In addition, we studied
the susceptibility of LDL to oxidation in vitro and LDL particle size in FCHL patients with
different lipid phenotypes as well as association between HDL oxidation parameters and serum
PON1 in FCHL. 
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2. REVIEW OF THE LITERATURE 
2.1 General outlines of lipoprotein metabolism
 
The major lipids in the plasma are fatty acids, triglycerides (TG), cholesterol (free and esterified
cholesterol) and phospholipids (PL). They are important in maintaining the structure of cell
membrane (cholesterol, phospholipids), steroid hormone synthesis (cholesterol), and energy
metabolism (TG and fatty acid). Since lipids are not water-soluble, they are transported in the
plasma in association with proteins as lipoproteins. Lipoproteins consist of a hydrophobic core
of TG and cholesterol esters (CE) surrounded by a hydrophilic surface of free cholesterol (FC),
phospholipids and apolipoproteins. Plasma lipoproteins are typically classified into five major
subclasses on the basis of their densities. Table 1 outlines the features of these lipoprotein
species; chylomicrons (CM), very low-density lipoproteins (VLDL), intermediate-density
lipoproteins (IDL), low-density lipoproteins (LDL) and high-density lipoproteins (HDL). Some
lipoprotein subclasses can be further separated by particle density or size, electrical charge, or
apolipoprotein content. 
Table 1. Physical properties, lipid and apolipoprotein composition of human plasma lipoproteins
Exogenous
lipids Endogenous lipids
CM VLDL IDL LDL HDL
Density (g/ml) <0.96 0.96-1.006 1.006-1.019 1.019-1.063 1.063-1.21
Diameter (nm) 75-1200 30-80 25-35 22-28 5-12
Elecphoretic mobility 0 Pre-β ’broad β’ β α, Pre-β
Composition (%)
  TG 86 55 23 6 5
  PL 7 18 19 22 33
  CE 4 12 29 42 17
  FC 2 7 9 8 5
  Protein 2 8 19 22 40-55
Main apolipoproteins A-I, A-IV,
B-48, C, E
B-100,
C, E
B-100, C, E B-100 A-I, A-II, C, E
Source Intestine Liver Lipolysis of
VLDL
Lipolysis of
VLDL, via
IDL
Liver, intestine;
lipolysis of
CM & VLDL
 
CM are produced postprandially in the intestinal epithelial cells, and they transport dietary TG,
cholesterol and fat-soluble vitamins to the liver and peripheral tissues [28]. TG are the major
constituent of the CM particles. ApoB-48, a specific apolipoprotein marker of CM, is
synthesized in the gut like apoA. ApoCII and apoE are transferred to CM from HDL in the
circulation. TG in CM are hydrolyzed by the enzyme lipoprotein lipase (LPL), resulting in the
formation of CM remnants which are taken up by the hepatic cells [29]. The cellular uptake of
CM remnants is mediated by multiple interactions of apoE and LPL with heparan sulfate
proteoglycans (HSPG), the LDL receptor and the LDL receptor-related protein (LRP) [30]. 
VLDL particles are synthesized in the liver. VLDL consists mainly of TG, and also contains
some cholesterol, one apoB-100 molecule, apoCs and apoE. The apoE and some of the apoCs
are transferred from HDL to VLDL. ApoB-100 is specific for VLDL and is synthesized in the
liver. In the circulation, VLDL shares the catabolic pathway with CM and competes for LPL
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[29]. As VLDL particles become smaller, phospholipids, free cholesterol and apolipoproteins are
released from their surfaces and transferred to HDL [31]. Recent data indicate that plasma
phospholipid transfer protein (PLTP) is responsible for the transfer of post-lipolytic surface
components of triglyceride-rich lipoproteins (TRLs) to HDL [32]. During lipolysis, VLDL is
converted to the denser particles, IDL, and finally transformed via hepatic lipase to LDL [31]. In
this cascade, apolipoprotein B (apoB) remains tightly associated with the particle.
HDL is synthesized primarily in the liver and small intestine. HDL precursor is (nascent)
discoidal particle [28] that comprises phospholipid, cholesterol, apoE and apoA, but is devoid of
cholesterol ester [33]. The nascent HDL is also formed during lipolysis of TRLs [31]. It becomes
mature spherical HDL by trapping cholesterol ester into the core of the particle with the help of
the enzyme, lecithin:cholesterol acyltransferase (LCAT), which catalyzes the transfer of free
fatty acyl group from phosphatidylcholine (PC) to free cholesterol with the formation of lyso-PC
and cholesterol ester [34,35]. 
HDL consists of a heterogeneous group of particles with varying density and size (diameter
range, 5-12 nm). HDL subclasses can be separated either by density gradient ultracentrifugation
(DGUC) according to their density, or by gradient gel electrophoresis (GGE) according to the
size. Two major HDL subclasses can be separated by sequential or gradient ultracentrifugation,
namely HDL2 (d=1.063-1.125 g/ml) and HDL3 (d=1.125-1.210 g/ml). The large and lipid-
enriched HDL2 are converted into smaller HDL3 by cholesteryl ester transfer protein (CETP)-
mediated export of cholesteryl esters from HDL into apoB-containing lipoproteins, by scavenger
receptor B1 (SR-B1)-mediated selective uptake of cholesteryl esters into liver, and by hepatic
lipase (HL)- or endothelial lipase (EL)-mediated hydrolysis of HDL-associated phospholipids
[36]. In contrast, HDL3 can be converted into HDL2 by a fusion reaction mediated by PLTP
[36,37] and by entry of CE due to the LCAT reaction [31,38]. HDL2 and HDL3 can be further
classified by gradient gel electrophoresis into: HDL2b (9.7-12.0 nm), HDL2a (8.8-9.7 nm),
HDL3a (8.2-8.8 nm), HDL3b (7.8-8.2 nm), and HDL3c (7.2-7.8 nm) [39,40]. HDL can also be
categorized to LpAI that contain only apoAI and LpAI/AII that contain both apoAI and apoAII,
by immunoaffinity chromatography, according to apolipoprotein composition [36]. In addition,
HDL can be distinguished into α- and pre-β HDL particles according to the particle surface
charge [41].
HDL has various potentially antiatherogenic properties, including reverse transport of
cholesterol from cells of the arterial wall to the liver [42,43], inhibition of LDL oxidation by
HDL-bound PON1 [44,45], regulation of coagulation and fibrinolysis and inhibition of platelet
activation [46], neutralization of endotoxin or lipopolysaccharide [37], and inhibition of the
chemotaxis of monocytes and the adhesion of leukocytes to the endothelium via HDL [46]. The
different antiatherogenic functions are exerted by different components of the HDL, namely
apolipoproteins, phospholipids, enzymes or lipid transfer proteins [46,47]. 
Lipoprotein (a) [Lp(a)] is a lipoprotein particle, which is similar to low density lipoprotein
(LDL), but also contains a distinctive glycoprotein, apolipoprotein (a) [apo(a)], that is linked
through a disulfide bridge to apoB [48]. Because Lp(a) has LDL as its component, oxidized
Lp(a) is avidly taken up by the scavenger receptor pathway and promotes cholesterol delivery
into the artery wall [49]. In addition, Lp(a) may also promote thrombosis because it has
structural similarities with plasminogen and competes with plasminogen for binding sites on
cells [48,49]. Finally, Lp(a) has been shown to be able to proteolytically degrade human LDL
[50,51]. 
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2.2 Low density lipoprotein (LDL)
2.2.1 LDL metabolism 
LDL particles are the main carriers of cholesterol in the circulation and play the key roles in the
cholesterol transfer and metabolism. Most LDL particles originate from the metabolism of TRLs.
In VLDL-IDL-LDL cascade, the particle is depleted of TG by the action of LPL and HL. In
addition, the particle loses most of the associated apolipoproteins [52]. Only apoB-100, the
essential structural protein, remains in the particle [52]. HL is important in the conversion of IDL
into LDL [52]. In addition, LDL can also be synthesized directly by the liver [21]. 
LDL can pass through the junctions between capillary endothelial cells and bind to LDL receptor
on cell membranes that recognize apoB-100 [28]. The subsequent uptake of LDL into the cells is
followed by lysosomal degradation with release of free cholesterol into the cytosol [52]. LDL
receptors are saturable and subject to down regulation by an increase in intracellular cholesterol
[53]. The LDL receptor expression regulates the plasma level of cholesterol [52]. The defects of
LDL receptor and its function cause familial hypercholesterolemia, a genetic disorder in which
the LDL receptor activity is reduced either because of a reduced number of LDL receptors, or
formation of structurally altered LDL receptors [54]. LDL particles are cleared from the
circulation either by hepatic or extrahepatic pathway. Liver takes up 75% of LDL; about 75% of
this removal are receptor mediated, and 25% nonreceptor-mediated [55]. Two third of the
extraphepatic uptake is receptor-mediated, and one third nonreceptor-mediated. 
In addition to classical LDL receptors, macrophages derived from circulating monocytes can
take up LDL via scavenger receptors. Scavenger receptors recognize chemically and biologically
modified lipoproteins, typically acetylated LDL [56,57] and oxidized LDL [5]. Some data have
shown that nonoxidative modification of LDL, like the formation of heparin proteoglycan-LDL
complex, can also induce uptake of LDL by macrophage through scavenger receptor-mediated
endocytosis or phagocytosis [58-60]. Unlike LDL receptor, the expression of scavenger receptor
is not down regulated by cellular cholesterol content [57], and therefore result in the intracellular
lipid accumulation and consequently induce foam cell formation (Figure 1) [57].  
2.2.2 Structure and biochemical composition of LDL
LDL is a spherical particle with a diameter of 22-28 nm and density of 1.019-1.063 g/ml. The
hydrophobic central core of LDL particles contains approximately 1600 molecules of CE and
170 molecules of TG. It is surrounded by a monolayer of about 700 phospholipid molecules,
consisting primarily of PC, small amounts of sphingomyelin (SM), lyso-PC,
phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidylinositol (PI), and 600
molecules of free cholesterol (FC) and one apoB-100 molecule [61,62]. Since apoB-100 is the
ligand for LDL receptor, it plays a crucial role in LDL metabolism. On average, LDL particles
contain 37-45 % CE, 9-11 % FC, 5-11 % TG, 18-24 % phospholipids and 20-24 %
apolipoprotein (i.e. apoB-100) [62]. 
About half of the fatty acids in LDL are polyunsaturated fatty acids (PUFAs), mainly linoleic
acid with minor amounts of arachidonic acid and docosahexaenoic acid. These PUFAs are
protected against free radical attack and oxidation by antioxidants, primarily α-tocopherol (6
molecules per LDL particle), with minor amounts of γ-tocopherol, carotenoids, cryptoxanthin,
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and ubiquinol-10 [62]. The amount of PUFAs and antioxidants varies significantly within
individuals, resulting in a great variation in LDL oxidation susceptibility.
2.2.3 LDL subfractions and their properties 
The heterogeneity of LDL has been recognized for more than two decades [63]. LDL can be
fractionated into subclasses by DGUC [64], by GGE [64], by proton nuclear magnetic resonance
spectroscopic method [65], and by size exclusion chromatography [66]. 
For practical purposes, LDL can be separated into three fractions by DGUC: large buoyant LDL
(d=1.025-1.034 g/ml), intermediate size and density LDL (d=1.034-1.044 g/ml), and small dense
LDL (d=1.044-1.060 g/ml) [67]. With GGE method, Austin et al [8] have characterized two
distinct LDL subclasses: pattern A and pattern B. In pattern A, the major peak of LDL particle
diameter is greater than 25.5 nm [8]. In contrast, in pattern B, the major peak of LDL diameter is
less or equal to 25.5 nm [8]. GGE can also be used for determination of the LDL peak particle
diameter when the LDL particle size is used as a continuous variable [66].   
The size of LDL subfractions reduces with an increase in density, in parallel with the reduction
in the ratio of lipid/protein [68,69]. From lightest to densest particles the core composition
changes from principally cholesterol ester to one that is more TG-rich [68]. Calculation of the
ratio of the particle contents of cholesterol (free and esterified cholesterol) molecules and protein
demonstrated that it is significantly higher in buoyant LDL (2750/1 apoB) as compared to dense
(2100/1 apoB) [69]. The diameter of human LDL particles correlates positively with the molar
ratio of phospholipid/apoB in LDL suggesting that phospholipid content is also an important
determinant of LDL particle size [70]. There are distinct and constant differences in the electrical
charge of LDL subfractions. Negative charge increases with increasing density of LDL particle
[21].   
2.2.4 Small dense LDL and its regulating factors 
Kinetic studies have shown that large buoyant VLDL1 particles are the precursor of small dense
LDL, and the long residence time of VLDL1 particles favours the lipid exchange [71]. In the
metabolic process (Figure 1), CE remains in the core of LDL particle, but part of CE is
transferred by CETP to VLDL in exchange for TG. Correspondingly, LDL particles become
enriched in TG that is a better substrate for HL [21,66,68,69]. Thereafter (Figure 1), HL
remodels the large LDL particles by hydrolysis of TG in the core and phospholipids on the
surface to convert them to smaller, denser particles [21,66,68,69]. Since LPL determines the
hydrolytic rate of TG-rich lipoproteins, it may have an indirect impact on the LDL subfraction
distribution [68]. 
The heritability of LDL particle size is estimated in twin studies to range from 30% to 50% [72].
These data indicated that both genetic and environmental factors are important determinants for
the LDL subclasses [72]. Linkages of LDL particle size phenotypes to several candidate gene
loci have been reported [73-78]. To date, the most common consistent evidence for linkage has
been found on chromosone 19p [76,77], the apoCIII gene locus on chromosome 11 [75,76] and
the CETP gene on chromosome 16 [76,78]. Thus, multiple genes may contribute to
determination of LDL subfraction profiles in plasma [79]. 
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In addition, LDL particle size and density distribution have been shown to be affected by age,
gender, diet, hypertriglyceridemia, obesity, insulin resistance, hormone status, and drugs
[21,66,69,72,80]. LDL particle size correlates strongly with insulin sensitivity in obese subjects
[81,82], in diabetics [83,84] and even in normoglycemic men [85]. However, in multiple
regression analysis insulin sensitivity has not been independently correlated with LDL particle
size after adjustment for plasma TG and HDL [85]. Thus, this association reflects complex
interactions between insulin resistance and lipid metabolism. In addition, drugs like beta-
blockers and lipid lowering agents can also influence LDL particle size [66]. Fibrates [21,66,69]
and some statins [25,86] therefore have been used to modulate the LDL particle size in some
clinical studies. 
Figure 1. Schematic illustration of the formation of small dense LDL and the hypothesis of
“LDL oxidation” in the atherogenesis. See text (chapter 2.2 and 2.3) for explanation. VLDL,
very low-density lipoprotein; TG, triglyceride; CE, cholesterol ester; CETP, cholesteryl ester
transfer protein; LDL, low-density lipoprotein; HL, hepatic lipase; PON1, paraoxonase-1; HDL,
high-density lipoprotein.
2.2.5 Atherogenic characteristics of small dense LDL
Small dense LDL is bound less avidly by the LDL receptor than large buoyant LDL resulting in
decreased hepatic clearance and a longer residence time in plasma [21,69,87]. The filtration rate
of LDL particles into the arterial intima is inversely related to particle size. Small dense LDL
particles therefore may penetrate more easily into the subendothelial space of artery wall from
the circulation (Figure 1) [69,88]. Small dense LDL particles contain less phospholipids and free
cholesterol in their surface monolayer than do large buoyant LDL particles. This difference in
lipid content appears to induce changes in the conformation of apolipoprotein B-100, leading to
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exposure of proteoglycan-binding regions [22,89]. This may give small dense LDL particles
increased binding affinity to arterial proteoglycans. The end-result is trapping of these particles
in the arterial extracellular matrix [22]. The retention of LDL in the subendothelial space has
been recently suggested to be the initiating event in the early stage of atherogenesis [90,91]. In
addition, small dense LDL particles are more susceptible to in vitro oxidation than large LDL
[92,93]. This increased LDL susceptibility to oxidation may be due to either reduced content of
antioxidants (vitamin E and ubiquinol-10) or increased content of PUFA in the small dense LDL
[21]. In addition, small dense LDL particles may also promote the thromboxane synthesis and
further influence platelet aggregation [94]. 
2.2.6 LDL particle size and CAD risk
The predominance of small dense LDL is associated with a two- to three-fold increase of CAD
risk [8,72,95]. Several prospective studies in different population cohorts have demonstrated that
small LDL particle size at baseline was a significant predictor for the development of CAD
[24,96,97]. In some studies, the association between LDL particle size and increased risk for
CAD is independent of other lipid parameters [24,98,99]. 
Although most studies suggest that small dense LDL particles are especially atherogenic, there
are additional possibilities to be considered. Small dense LDL often coexists with
hypertriglyceridemia and low level of HDL; this triad has been nominated as the atherogenic
lipoprotein phenotype (ALP) or proatherogenic lipoprotein profile [26]. These three
abnormalities are metabolically intertwined. Each one may be atherogenic, and consequently it is
difficult to dissect out their relative contribution to atherogenesis. Thus, LDL particle size may
merely be a marker of other lipid abnormalities [27]. On the other hand, the detection of small
LDL particles usually means that more LDL particles are present than indicated by LDL-
cholesterol level. Thus the number of LDL particles is more closely related to CAD risk than are
levels of LDL cholesterol. This excess of LDL particles can account in part for the independent
increment in CAD risk accompanying small LDL [26]. 
Further evidence for the clinical relevance of small dense LDL comes from clinical trials that
have evaluated effects of lipid-lowering therapy on progression of CAD. Miller et al reported
that the reduced progression of coronary angiography with lipid-lowering treatment was
observed in the subgroup of subjects with small dense LDL, but not in those with more buoyant
LDL, despite comparable LDL cholesterol lowering in the two groups [100]. In subjects with a
familial history of atherosclerosis and elevated plasma apoB levels, Zambon et al found that a
regression in coronary artery stenosis with lipid-lowering drugs is most strongly related to the
change in LDL density independently of changes in other risk factors [25]. 
2.3 Oxidative modification of LDL, oxidative stress and antioxidants
2.3.1 Hypotheses of atherogenesis and “LDL oxidation”
The molecular and cellular mechanisms for the initiation of atherosclerosis are still debated. At
present, three competing hypotheses have been proposed to explain the initiating events in
atherosclerosis. The “response-to-injury” hypothesis emphasizes the role of apoB-containing
lipoproteins and proposes that endothelial dysfunction or denudation is the first step in
atherogenesis [101,102]. The “LDL oxidation” hypothesis emphasizes the significance of the
oxidation of LDL in atherogenic responses, such as the recruitment of macrophages and other
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inflammatory cells to the subendothelial spaces [5,103]. The “response-to-retention” hypothesis
proposes that the initiating event in early atherosclerosis is the subendothelial retention and
accumulation of apoB-containing lipoproteins [90,91]. These hypotheses are by no means
mutually exclusive, and may even be considered mutually compatible.
In the early 1980s, evidence emerged that cholesterol accumulation in the foam cells was
probably due to the uptake of modified form (acetylation in vitro) of LDL via the scavenger
receptor A, but not due to the uptake of native LDL via the LDL receptor [56,103]. Scavenger
receptor A, unlike the LDL receptor, is not down regulated by the cellular cholesterol content
[57,103]. More physiologically relevant modifications of LDL that can result in its cellular
uptake via scavenger receptor can be induced by incubation of LDL with endothelial cells or
smooth muscle cells [56,103]. This cell-mediated modification can be duplicated by incubation
of LDL with transition metals and was shown to be oxidative in nature [5,103]. Importantly, this
modification can be completely blocked by antioxidant [103]. Other modifications that can
enhance LDL uptake by macrophages in vitro include glycation, self-aggregation, immune-
complex formation, and complex-formation with proteoglycans [60]. In addition, the proteolysis
of LDL with release of apoB-100 fragments renders the particles sufficiently unstable to fuse and
thus to become liable to ingestion by macrophages [104].
The “LDL oxidation” hypothesis emphasizes the significance of the oxidation of lipoprotein in
the initiation and progression of atherosclerosis [103]. Whether the oxidized LDL is indeed
involved in the initiation of atherosclerosis is a debated question [4,90,91], but there are no
doubt that the oxidation of lipoproteins occurs in vivo (Figure 1) [4,91,105]. Oxidized LDL,
together with other oxidatively modified lipids and degradation products, can contribute to the
pathophysiology of the atherosclerosis by multiple mechanisms, including its proinflammatory,
immunogenic and cytotoxic properties [4].
2.3.2 Mechanisms of LDL oxidation
Lipid oxidation products have been found in atheroma [4,9]. It has been speculated that the
oxidation of LDL may happen in the subendothelial space of the arterial wall, a pro-oxidative
environment [9,103]. Several studies [106,107] have demonstrated that small amounts of
oxidized LDL may circulate in human blood [9,108]. This does not necessarily mean that LDL is
oxidized within the plasma compartment; the LDL can undergo oxidative modification in the
artery wall or at any extracellular site and then return to the plasma compartment [9].
The cells of the artery wall, including macrophages, endothelial cells and smooth muscle cells,
secrete oxidative products that can initiate lipid oxidation [4,9,103]. Monocyte-derived
macrophages are known to produce oxidizing radical species. In early vascular lesions,
interstitial lipoproteins would be exposed to a large surface area of resident macrophages.
Monocyte/macrophages can carry out both metal-dependent and metal-independent oxidative
processes [9,109]. In contrast, endothelial cells represent a monolayer with only one face
exposed to the intima, and smooth muscle cells are sparse in early lesions. The mechanisms
described for endothelial or smooth muscle cell-mediated oxidation of LDL require exogenous
metals [9,109]. Although it is still unclear which oxidative mechanisms or radical species are
involved, potential candidates include ceruloplasmin, 12/15-lipoxygenase (LO),
myeloperoxidase, NADPH oxidase, reactive nitrogen species, or other macrophage-generated
oxidants [4,9,109], and cytochrome p450 [110,111]. In addition, catalytically active copper and
iron (e.g. Cu2+ or Fe2+) have been found in atherosclerotic lesions, and the copper-carrying
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protein of plasma (ceruloplasmin) can catalyze LDL oxidation [109,112]. The chemical studies
of plaque composition suggest that different mechanisms of LDL oxidation may predominate at
different stages of plaque development [109]. 
LDL oxidation has been studied extensively in vitro using a variety of agents to initiate the
reaction. These agents include copper or iron ions, ceruloplasmin, 15-lipoxygenase,
peroxynitrite, the free radical generators 2,2’-azobis(2-amidinopropane) dihydrochloride
(AAPH) and 2,2’-azobis(2,4-dimethyl-valeronitrile) (AMVN), as well as endothelial cells,
smooth muscle cells and macrophages [113]. The most common method for the initiation of
LDL oxidation in vitro involves incubation with copper ion [113]. In the copper-induced LDL
oxidation, copper ions have been assumed to participate in redox cycling reactions with
contaminating or pre-formed endogenous lipid hydroperoxides (LOOH) [62,113]. The peroxyl
(LOO.) and alkoxyl (LO.) radicals generated in the above reactions are believed to initiate
oxidation of the parent polyunsaturated fatty acid through hydrogen-atom capture [113]. The
copper oxidized LDL exhibits chemical and biological properties similar, if not identical, to
macrophage-modified LDL [62]. The decomposition of lipid hydroperoxides formed by CuSO4-
induced LDL oxidation will result in formation of reactive aldehydes, e.g., malondialdehyde and
4-hydroxynonenal [114]. Interaction of these aldehydes with positively charged ε-amino groups
of lysine residues in apoB-100 renders the LDL more negatively charged, resulting in decreased
affinity for the LDL receptor and increased affinity for scavenger receptor [114]. 
2.3.3 Factors that determine the resistance of LDL to oxidation
In vivo, oxidation of LDL is influenced by both LDL composition (intrinsic factors) and the
microenvironment in which the LDL particle is located (extrinsic factors). Among the intrinsic
factors, the fatty acid composition of LDL is of prime importance. A high proportion of
polyunsaturated fatty acids (PUFAs, i.e. linoleic acid 18:2) confers greater susceptibility to
oxidation, while a high proportion of monounsaturated (MUFAs, i.e. oleic acid 18:1) or saturated
(SFA, i.e. palmitic acid 16:0) fatty acids protects against oxidation (Figure 2) [115,116]. Since
the propagation phase of LDL oxidation begins after the endogenous antioxidants have been
consumed, susceptibility to oxidation is also highly dependent on the antioxidant content in
LDL, for instance α-tocopherol, ubiquinol-10, β-carotene and retinol (Figure 2) [117,118]. LDL
particle size is another factor that has been shown to modify oxidative susceptibility. The small
dense LDL particles are more susceptible to oxidation than large buoyant LDL particles, which
may to a large extent be due to differences in antioxidant content [92,93]. In addition, the
existence of pre-formed lipid hydroperoxides in LDL may also influence the oxidative
susceptibility of the particle [62,113,119,120]. Notably, the in vitro assessment of the
susceptibility of LDL to oxidation takes into account only those factors intrinsic to LDL. 
LDL susceptibility to oxidation in vivo is also influenced by the particle's immediate
microenvironment, including local antioxidant concentrations, transition metal availability, pH
and the presence of HDL and HDL-associated enzymes. The HDL-combined enzymes, PON1,
paraoxonase-3 (PON3), platelet-activating factor acetylhydrolase (PAF-AH) and LCAT, have
shown the ability to protect LDL against oxidation in vitro by preventing the generation of
phospholipid hydroperoxides [114,121]. 
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Figure 2. Schematic illustration of the chemical composition of LDL and the principal lipid-
soluble antioxidants and fatty acids in LDL.
2.3.4 The nature of  “oxidized LDL”
“Oxidized LDL” is not a single, chemically homogeneous entity, but represents a spectrum of
oxidized particles with variable content [122,123]. The precise composition of oxidized LDL
depends both on the nature and amount of oxidant used, as well as oxidant concentration,
duration and conditions of exposure. When LDL is incubated with Cu2+ over time, there is a
continuous spectrum of degrees of oxidation [103]. Thus oxidized LDL used in the biological
experiments can be categorized into minimally modified, mildly oxidized, moderately oxidized,
and oxidized LDL [122]. It is generally believed that "fully oxidized LDL" does not exist in the
circulation. In contrast, circulating minimally modified LDL (MM-LDL), in which oxidative
modification has not been sufficient to cause changes recognized by scavenger receptors, has
been described by several groups [106,107,124]. Subsequently, several groups have confirmed
the presence of oxidation-specific epitopes on plasma LDL, such as MM-LDL [108].  
Oxidized lipoproteins contain a number of oxidation products (oxidized phospholipids and
oxysterols) that have been found in the artery wall and are able to mediate processes associated
with different stages of atherogenesis [125]. When the sn-2 fatty acids of phospholipids are
oxidized by free radicals, several different types of oxidative products are formed. These include
phospholipids containing fatty acid oxidation products (these will be referred to as oxidized
phospholipids, e.g. isoprostanes), lysophospholipids, and fragmentation products of fatty acid
oxidation (e.g. malondialdehyde) [125]. Oxysterols in plaque are derived from the diet and/or
from in vivo oxidation, or (e.g. 27-hydroxycholesterol) are formed enzymically during
cholesterol catabolism [126]. Both oxidized phospholipids and oxysterols are toxic and possess
various biological activities that are potentially proatherogenic. 
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2.3.5 Atherogenetic properties and in vivo evidence of oxidized LDL 
Oxidized LDL has many characteristics that potentially promote atherogenesis [9,103]. Firstly,
oxidized LDL is recognized by the scavenger receptors and can therefore give rise to foam cells
(Figure 1) [9,103]. Secondly, oxidized LDL stimulates endothelium to secrete monocyte
chemotactic protein 1 (MCP-1), which induces the infiltration of monocytes into the
subendothelial space [9,103]. Oxidized LDL can also induce migration and proliferation of
smooth muscle cells and impede endothelial cell migration [9,103]. Finally oxidized LDL may
interfere with endothelium-mediated relaxation and stimulate platelet adhesion and aggregation
through inhibition or reduced endothelial production of nitric oxide (NO) [9,103]. Some
components of oxidized LDL, like oxysterols or phosphatidylcholine, especially if ceramide
presents, may induce cell injury by both apoptotic and necrotic pathways [114,127]. These pro-
atherogenic properties of oxidized LDL may explain the great variability in the incidence of
CAD at any level of plasma cholesterol and why the modification of LDL plays an important
role in the development of atherosclerosis. 
There is substantial evidence that oxidized LDL is present in vivo within atherosclerotic lesion
but not in normal arterial wall [4,9]. LDL that is extracted from human and animal
atherosclerotic lesions shares the characteristics with respect to the physical, chemical,
immunological and biological properties with oxidized LDL [128,129]. Monoclonal antibodies
against oxidation-specific epitopes in oxidized LDL have been used to show extensive
immunostaining and the presence of oxidized LDL in atherosclerotic lesions in both human and
animals [4,9]. Autoantibodies to epitopes of oxidized LDL, reflecting the fact that oxidized LDL
is very immunogenic, are found in plasma of animals and patients with various manifestations of
atherosclerosis [4,9]. Products of lipid peroxidation, such as oxidized cholesterol, fatty acids,
phospholipids and isoprostanes, are found in atherosclerotic lesions and plasma, and some
degradation products of these oxidized lipids have been demonstrated in urine [4,9]. The ability
of lipid-soluble antioxidants to inhibit atherogenesis in hypercholesterolemic animal models is
one of the strongest lines of evidence for the oxidation hypothesis [4,17]. 
2.3.6 Susceptibility of LDL to oxidation in vitro
In 1989, Esterbauer et al [130] described an in vitro spectrophotometric method for the kinetics
of LDL oxidation in which the CuSO4-induced oxidation of LDL is continuously monitored by
following the formation of conjugated dienes at the wavelength of 234 nm. The reaction occurs
in three phases [130]: an initial lag phase (consumption of endogenous antioxidants), a
propagation phase (rapid oxidation of unsaturated fatty acids to lipid hydroperoxides) and a
decomposition phase (lipid hydroperoxides are converted to reactive aldehydes, e.g.,
malondialdehyde, 4-hydroxynonenal) [114]. During the lag and propagation phase and the early
part of the decomposition phase, the time course of the diene formation fully reflects the lipid
hydroperoxides time profile [62]. This in vitro technique does not measure the presence of
oxidation products in the lipoprotein, but provides a measure of the intrinsic susceptibility (lag
time) of the lipoprotein to be oxidized (Table 2) [62]. This method has been widely used in
clinical and biochemical research. In some clinical studies, the severity or progression of CAD is
related to the susceptibility of LDL to oxidation in vitro [10,131]. However, in another study, it
was only marginally associated with the extent of coronary atherosclerosis [11]. 
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Recently, Ahotupa et al have developed a method for determining LDL baseline conjugated
dienes, as a measure of its in vivo oxidation (Table 2) [132]. They have reported that the
increased LDL baseline conjugated dienes is associated with coronary and carotid
atherosclerosis [133,134]. 
2.3.7 Autoantibodies against MDA-LDL or oxidized-LDL
When polyunsaturated fatty acids in phospholipids and cholesteryl esters in the lipoprotein
undergo peroxidation, highly reactive breakdown products are formed, such as malondialdehyde
(MDA) and 4-hydroxynonenal (4-HNE) [62]. These may form covalent adducts with lysine
residues of apoB. Neoepitopes generated by the modification of lysine are immunogenic [135].
Antisera and monoclonal antibodies against MDA-lysine or 4-HNE-lysine epitopes can therefore
be generated by immunising guinea pigs and mice with homologous LDL modified in vitro with
MDA or 4-HNE [135]. These antibodies were instrumental in establishing the presence of
OxLDL in atherosclerotic lesions. 
An assay measuring the level (the titer) of autoantibodies against neo-epitopes in LDL oxidized
by copper or modified by MDA was developed as an indirect indication of in vivo oxidation of
LDL (Table 2). Salonen et al reported an association between titers of autoantibodies against
extensively oxidized LDL and the progression of carotid atherosclerosis [136]. However, data on
the relationship between autoantibody titer and coronary or carotid atherosclerosis have not been
consistent [137-140]. There is a great variability in the apparent titer of antibodies from the same
serum sample when different oxidized LDL preparations were used. So far there is no agreement
how the oxidized LDL used in the different immunoassays should be generated in vitro and what
its composition should be [114].  
Recently, several groups have developed more sensitive ELISA methods to “directly” measure
the small amount of circulating oxidized LDL in plasma (Table 2) [141-143] or in plasma LDL
[144]. In these assays, different monoclonal antibodies against a neo-epitope in the aldehyde-
substituted apoB-100 moiety of oxidized LDL [141,142] or against an epitope in the oxidized
phosphatidylcholine [143,144] are used to recognize a single epitope in the circulating oxidized
LDL. However, there are several caveats concerning the extent of modification and
reproducibility of the reference ox-LDL preparations that are used as standards for these assays.
There is only one epitope measured in these assays whereas potentially many epitopes may exist
on any individual LDL, and different populations of ox-LDL may exist. The quantitation of ox-
LDL will be improved when the epitopes are better delineated and the reference standard can be
a stable pure preparation of the epitope [145].
2.3.8 Measurement of F2-isoprostanes
F2-isoprostanes are prostaglandin isomers produced from arachidonic acid by a free radical-
catalyzed mechanism [146]. They have been found in human atherosclerotic plaque [147]. Both
the plasma F2-isoprostanes and urinary metabolite of F2-isoprostanes can be measured by mass
spectrometry and ELISA methods and have been used as the marker of oxidative stress or lipid
peroxidation in vivo (Table 2) [146,148]. There are several favorable attributes that make these
measurements as reliable indices of oxidative stress in vivo: (1) F2-isoprostanes are specific
products of lipid peroxidation; (2) they are stable compounds and are detectable in all normal
biological fluids and tissues, allowing the definition of a normal range; (3) their formation
increases dramatically in vivo in a number of animal models of oxidative injury and their
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formation is modulated by antioxidant status; and (4) their levels are not effected by lipid content
of the diet [148]. Increased levels of F2-isoprostanes have been reported in smokers, and in
subjects with diabetes, hyperlipidemia and hyperhomocysteinemia [148]. The measurement of
urinary metabolite of F2-isoprostanes is a non-invasive index of lipid peroxidation or oxidative
stress in vivo and feasible in large clinical trials.  
2.3.9 MDA measurement with thiobarbituric acid reactive substances (TBARS)
Another widely used index of lipid or lipoprotein peroxidation is the measurement of the
malondialdehyde (MDA) by TBARS assay with spectrophotometer [62]. Many investigators
have used it to measure the degree of lipid or lipoprotein oxidation in vivo (Table 2) [62,146].
MDA is a secondary product of lipid peroxidation. This assay is non-specific and can be
interfered by other compounds in biological sample [146]. However, the plasma TBARS have
shown to be increased in CAD patients as compared to healthy controls in some studies [149]. 
Table 2. Assessment of Lipid peroxidation
Sample Measurement
Susceptibility of LDL,
HDL to oxidation
in
vitro
LDL
HDL
Intrinsic susceptibility of isolated LDL or HDL to
oxidation 
Baseline diene
conjugation
in
vivo
LDL LDL baseline conjugated dienes are a measure of its
in vivo oxidation 
Antibodies to against
MDA- or oxidized- LDL
in
vivo
Serum Antibodies against multiple neo-epitopes in LDL
oxidized by Copper or modified by MDA. 
Circulating oxidized
LDL (ELISA)
in
vivo
Serum Recognizing a single epitope in the circulating
oxidized LDL by using monoclonal antibodies
against a certain epitope in the oxidized LDL 
F2-Isoprostane in
vivo
Serum
Urine
Oxidation products of arachidonic acid (F2-
Isoprostane) in plasma or their metabolite in urine
TBARs in
vivo
Serum Measuring MDA, a secondary product of lipid
peroxidation (non-specific)
2.3.10 HDL-bound paraoxonase-1 and oxidation of LDL or HDL
Human serum PON1 is a glycoprotein of 354 amino acids with a molecular mass of 43 kDa
[150,151]. It is synthesized in the liver and combined with HDL in the circulation [152]. Since it
is extremely difficult to remove apoAI from PON1 during purification from human serum, PON1
is believed to be closely associated with apoAI [152,153]. Originally, PON1, as an enzyme, was
known for its hydrolytic activity with paraoxon and other organophosphate [154]. 
In 1990, Parthasarathy et al [155] reported that HDL has antioxidant activity and can inhibit the
oxidative modification of LDL. Mackness first proposed that HDL-bound enzyme PON1 may be
involved in lipid (phospholipid) metabolism, and identified that PON1 can inhibit lipid peroxide
generation in LDL (Figure 1) [44]. Thereafter, several other HDL associated enzymes, like PAF-
AH, LCAT and PON3 (a new paraoxonase gene family member) have also been found to be able
to inactivate LDL-derived oxidized phospholipids [114,121]. In addition, LCAT facilitates
formation of estrogen esters in HDL and may be important to antioxidant capacity of HDL [156].
All these enzymes may contribute to the antioxidant properties of HDL [121], however, only
PON1 has been the focus of extensive studies. Shih and co-workers reported that on a high-fat,
high-cholesterol diet, PON1-null mice were more susceptible to atherosclerosis than their wild-
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type littermates [157]. Moreover, Watson et al has reported that PON1 in HDL may protect
against the induction of inflammatory responses in artery wall cells by destroying biologically
active lipids in mildly oxidized LDL [158]. 
PON1 gene is located on the long arm of chromosome 7 [151]. The major genetic
polymorphisms of PON1 include the replacement of glutamine (Q) by arginine (R) at position
192, and that of leucine (L) by methionine (M) at position 55 [152,159]. The variants are
designated as PON1 192QR and 55LM. The frequencies of the PON1 alleles vary greatly across
human population [45]. There is wide inter-individual variation in the capacity of PON1 to
hydrolyze organophosphates. The PON1 192QR polymorphism appears to be the major
determinant of this variation [152,160]. PON1-R allozyme is more active towards some
substrates, such as paraoxon. PON1-Q is more active for other substrates, such as diazoxon and
nerve gas sarin and soman; whereas there is no discrimination between the allozymes for phenyl-
acetate substrate [161]. In addition, PON1 gene polymorphism may affect the antioxidant action
of PON1 [162]. Mackness et al observed that the protection against LDL oxidation by PON1-RR
HDL was higher than that by PON1-QQ HDL in the first 2 hours of incubation with CuSO4
[163]. However, the protective capacities of the two allozymes were switched later, the PON1-
QQ HDL being more protective than PON1-RR HDL after 6 hours of LDL oxidation [163].
Aviram et al have reported that PON1 Q and PON1 R allozymes may have different protective
characteristics against LDL oxidation [164]. Another genetic polymorphism of PON1 55LM
may also modulate the activity of the enzyme [162,165]. 
Table 3. Characteristics of different PON1 allozymes
PON1 Q or A allozyme
(Glutamine at 192)
PON1 R or B allozyme
(Arginine at 192) Two allozymes
Organophosphate
hydrolysing activity 
for different substrates
Higher for:
diazoxon, sarin, soman
Higher for:
methyl paraoxon,
paraoxon, EPN oxon,
chlorthion oxon, armine
Higher for:
phenyl acetate,
cholopyrifos oxon, 
2-naphthyl acetate
Phospholipid peroxide
hydrolysing activity
(antioxidant activity)
More lasting and stable
more efficient for
longer time
More sensitive
more efficient in a short
time
PON1 contains three cysteine residues, but only one, at position 284, has a free sulfhydryl group
that may be responsible for the phospholipid hydrolyzing activity of the enzyme [164]. The
structural requirement for the antioxidant activity of the PON1 is different from that required for
its arylesterase (ARE) and PON1 activities [164].
Recently, PON1 has been shown to be a member of a multigene family with two other PON1-
like genes, designated as PON2 and PON3, present on chromosome 7. The 3 PON genes share
about 65% similarity of sequence at the amino acid level [154,159,166]. PON1 is expressed
primarily in the liver. PON2, on the other hand, is expressed widely in a number of tissues,
including brain, liver, kidney, and testis, and may have multiple mRNA forms [166]. So far,
PON3 expression in human tissues has not been reported. Both PON1 and PON3 are HDL-
associated enzymes [166]; in contrast, PON2 is not associated with HDL [167]. Both human
PON2 and PON3 possess antioxidant properties, similar to those of PON1, and are capable of
preventing oxidative modification of LDL [166,167]. To date, only PON1 has been purified and
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characterized from human sources, and PON1 and/or ARE activities have not been reported for
human PON2 and PON3 [166]. 
The demonstration of links between PON1 and LDL oxidation launched great interest in the
possible role of this enzyme in atherosclerosis. Some [168-172], but not all [173-177], studies
have shown that PON1 192 genetic polymorphism (192QR) is associated with an increased risk
for CAD. A meta-analysis on 19 published studies on the PON1 192 genotype in CAD
demonstrated that the PON1 192R allele was associated with increased risk for CAD [178]. So
far, less data exists on the relationship between the PON1 55 genetic polymorphism (55LM)
with CAD, but again inconsistent results have been reported [165,177]. Mackness et al studied
PON1 activity, mass concentration and gene distribution in 417 subjects with angiographically
proven CAD and in 282 healthy controls [178]. They found that serum PON1 activity and mass
concentration were lower in the CAD patients than in the healthy controls regardless of PON1
genotype [178]. They suggested that the quality of the PON1 enzyme is a more important factor
in CAD than is the PON1 gene [178]. This concept was supported by the study of Jarvik and co-
workers who found that the measurement of PON1 activity seems to be a better prediction of
carotid artery disease than either the PON1 55 or PON1 192 genotype [179]. Recent evidence
has indicated that polymorphisms in the promoter region of the PON1 gene are important in
determining levels of PON1 [180] and the promoter polymorphism (C-107T) may also be
associated with increased risk for CAD [181,182]. In addition, missense variations of PON2
have also been reported, and significant associations were observed between PON2
polymorphisms (PON2, 311CS) and risk for CAD [169,183]. 
Although substantial evidence indicates that antioxidant activity of HDL-bound PON1 is of
importance [151], the anti-atherogenic function of PON1 in vivo is still unclear. HDL, due to its
small size, diffuses readily into interstitial fluid and the intimal space [184], the major site of
LDL oxidation in vivo [5]. HDL-bound PON1 may inactivate the preformed oxidized-lipids by
hydrolysing specific oxidized phospholipids (Figure 1) [151,185]. Since HDL is rich in
polyunsaturated phospholipids, HDL itself can also be oxidized, in the same manner as LDL,
under the oxidative stress [186], and consequently lose its anti-atherogenic ability [184] or even
be converted to a harmful and pro-atherogenic particle [187]. It has been reported that HDL-
bound PON1 can protect HDL itself, as well as LDL, from oxidative modification [188]. HDL
oxidation, however, has received less attention than LDL oxidation. 
2.4 Oxidative stress, antioxidants and antioxidant capacity
2.4.1 Oxidative stress and free radical-mediated damage
Oxidative stress is defined as an imbalance between the production of reactive oxygen species
(ROS) or free radicals and antioxidant defenses, which may induce tissue injury [189]. Free
radicals can be defined as any chemical species that contains unpaired electron. These unpaired
electrons increase the chemical reactivity of an atom or molecule [189,190]. Common examples
of free radicals include the hydroxyl radical (•OH), superoxide anion (•O2-), transition metals
such as iron and copper, nitric oxide (NO•), and peroxynitrite (ONOO-).       
Several different biochemical processes may be involved in the formation of free radicals within
the body: 1) reduction of molecular oxygen during aerobic respiration can yield superoxide and
hydroxyl radicals; 2) some chemical by-products during the oxidation of catecholamines and
activation of the arachidomic acid cascade produce electrons, which can reduce molecular
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oxygen to superoxide; 3) activated phagocytes can produce superoxide and hypochlorous acid
(HOCI); 4) nitric oxide can be produced by vascular endothelium and other cells [190,191]. 
Free radicals are inherently unstable and highly reactive molecules because of the presence of
unpaired electrons. As a result, they can react locally to accept or donate electrons to other
molecules to achieve a more stable state. Reaction of a radical with a nonradical (all biological
macromolecules, lipids, proteins, nucleic acids, and carbohydrates) produces a free radical chain
reaction with the formation of new radicals, which in turn can react with macromolecules [190].
Lipid peroxidation is perhaps the most extensively studied consequence of free radical attack. 
Reactive free radicals, e.g., the hydroxyl radical, have the capacity to abstract a hydrogen atom
(H•) from a methylene group (-CH2-) of fatty acids, leaving behind an unpaired electron on the
carbon (-•CH-) [190]. PUFAs are particularly prone to free radical attack because the presence
of a double bond weakens the carbon-hydrogen bond at the adjacent carbon atom. The remaining
carbon-centered radical undergoes molecular rearrangement resulting in a conjugated diene.
Conjugated dienes can combine with oxygen forming a peroxyl radical and initiate a chain
reaction that continues either until the substrate is consumed or the reaction is terminated by a
chain-breaking antioxidant such as vitamin E [62,190]. Oxidation of LDL results in extensive
fragmentation of LDL PUFAs with conjugation of the fragments to LDL apolipoprotein B and
phospholipids. 
2.4.2 Antioxidant defenses and antioxidant capacity
Living organism has developed a complex antioxidant network to counteract free radicals that
are detrimental to human life. Cellular antioxidant defenses include the superoxide dismutase
(SOD), glutathione peroxidase, and catalase enzymes [190]. The human blood antioxidant
defense system consists of ascorbic acid (ascorbate or vitamin C), α-tocopherol (vitamin E), β-
carotene, ubiquinol-10, uric acid (urate), bilirubin, albumin, protein-bound thiol (sulfhydryl)
groups, flavonoids [192,193]. In addition, some lipophilic antioxidants such as α-tocopherol, γ-
tocopherol, β-carotene, retinol and ubiquinol-10 are also found in cell membranes. Dietary
phytoestrogens, such as genistein and daidzein, may have antioxidant role in atherosclerosis
prevention [194]. 
The steady state balance between pro-oxidants and antioxidants is important to protect tissue or
biological macromolecules from the oxidation damage. This balance may be disturbed in case of
depletion of the antioxidants, which may occur endogenously or as a consequence of an
insufficient dietary intake. The imbalance between pro-oxidants and antioxidants or oxidative
stress has been associated with several disease states in man, including atherosclerosis, ageing,
hyperglycemia or diabetes, neurodegenerative disorders like Alzheimer’s disease, Parkinson’s
disease and various dementias, rheumatoid or chronic inflammatory diseases, and carcinogenesis
[195]. 
Oxidative stress can be assessed by measurement of reaction products of oxidative damage, like
lipid peroxidation, DNA oxidation, and protein oxidation. Assessment of lipid peroxidation
includes TBARS assays, conjugated dienes, hydroperoxides and F2-isoprostanes [146,190]. A
complementary approach is the measurement of major antioxidants such as α-tocopherol,
vitamin C, urate and thiol groups [190]. The ratio of pro- and anti-oxidants is also useful to
express the oxidative stress [196]. 
25
Total peroxyl radical trapping antioxidant capacity of plasma (TRAP) reflects the total combined
antioxidant capacity of all individual antioxidants [193,197]. Several methods have been
developed to measure the total antioxidant capacity of a biological sample. Wayner et al [198]
followed the peroxidation induced by 2,2'-diazobis (2-amidinopropane) dihydrochloride (AAPH),
a peroxyl radical generator, by monitoring oxygen consumption in a thermostated oxygen
electrode cell during peroxidation of oxidizable materials in serum. Valkonen and Kuusi
modified the assay to follow the formation of highly fluorescent 2,7-dichlorofluorescein (DCF),
that is converted from 2,7-dichlorofluorescein-diacetate (DCFH-DA) by free radicals, with
spectrophotometer [199]. In this assay, the length of the induction period (lag phase of the
sample to resist artificially induced peroxidation) is compared to that of an internal standard
(Trolox) and then quantitatively related to the antioxidant capacity of the plasma [198,199]. Cao
et al [193,200] developed a thermostated fluorescence method to quantitative the oxygen-radical
absorbing capacity (ORAC) by calculating an area-under-curve after the reaction between
substrate (phycoerythrins) and free radicals to completion. 
2.4.3 Antioxidants and the prevention of atherosclerosis 
Recently the LDL oxidation hypothesis has been tested in several prospective clinical trials. The
Cambridge Heart Antioxidant Study (CHAOS) [201] and the Secondary Prevention with
Antioxidants of Cardiovascular Disease in Endstage Renal Disease (SPACE) [202], have shown
that intake of vitamin E can significantly reduce the risk for nonfatal myocardial infarction in
patients with CAD [201] or reduce the cardiovascular events in renal failure patients [202].
However, there were no decreases in cardiovascular mortality and total mortality in the CHAOS
study [201], and the duration (1.4 years of follow-up) of these two trials was relatively short
[201,202]. In contrast, the Alpha-Tocopherol, Beta-Carotene Cancer prevention (ATBC) trial
[203] with low dose of vitamin E failed to prevent cardiovascular events in heavy smokers
without known CAD during a 5.3-year follow-up duration. The Gruppo Italiano per lo Studio
della Sopravvivenza nell’Infarto Miocardico (GISSI) trial [18] reported that, during a 3.5-year
follow-up, vitamin E supplementation had no significant effect on the composite end-point of
death, non-fatal myocardial infarction (MI) and stroke in 11324 patients with known MI.
Likewise, dietary supplementation with vitamin E had no beneficial effect on endpoints in the
Heart Outcomes Prevention Evaluation (HOPE) trial [19] in which 9541 patients with
symptomatic CAD were followed for 4.5 years. Recently, in the Heart Protection Study (HPS)
[20], administration of an antioxidant cocktail (vitamin E, vitamin C and beta-carotene) for over
the 5 years had no effect on any type of vascular end points, although this regimen increased
blood vitamin concentrations substantially. 
2.5 Influence of physical activity on LDL particle size and LDL oxidation
2.5.1 Physical activity, lipid metabolism and LDL particle size
Physical activity is associated with beneficial effects on lipids and lipoproteins [204-206], body
weight, blood pressure, insulin sensitivity [207,208], and coagulation parameters [209,210].
Consequently physical activity is related with the reduced prevalence of cardiovascular disease
[211-213]. In contrast, physical inactivity is associated with at least a twofold increase in risk for
CAD events [214]. The beneficial mechanisms provided by physical activity have been a topic of
great interest.
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Alterations in lipid and lipoprotein metabolism are influenced by the degree of fitness and
exercise intensity of the working skeletal muscle [215,216]. Regular aerobic training that elicits
1200-2200 kcal/week is effective at elevating HDL cholesterol (HDL-C) levels about 2-8 mg/dl
(0.05-0.2 mmol/l), and lowering TG levels by 5-38 mg/dl (0.06-0.43 mmol/l) [204]. However,
regular aerobic exercise did not show any significant influence on total or LDL cholesterol
levels.  In a recent large-scale study including 8283 male and 1837 female on a regular aerobic
training program, significant changes were reported for HDL-C and TC/HDL-C in both genders,
and TG levels in male, but no significant change was evident for LDL-C levels [217,218]. 
The responses of lipids or lipoproteins to a single bout of aerobic exercise have been highly
variable. Increases [219-221], decreases [222,223] or no change [224] in plasma TG levels have
been reported in different studies. The responses of plasma TC or LDL cholesterol
concentrations have also been variable [205,219-224]. In contrast, an increase in HDL-C
concentration has been observed more consistently [205,219-221,223,224]. 
In contrast to the aerobic exercise, anaerobic exercise (weight lifting or wresting etc.), especially
training above certain anaerobic threshold (blood lactate > 4 mmol/l), has no or even negative
effects on blood lipoprotein profiles [225]. 
Physical activity may increase the lipolysis of endogenous TG in adipose tissue and skeletal
muscle [216]. Exercise also has effects on the activity or expression of LPL [226,227], HL,
LCAT or CETP [205,228]. These changes are thought to play an important role in the
metabolism of lipoproteins or relative distribution of their subfractions [205,215,228]. Exercise
may therefore modulate the LDL subfraction distribution. Indeed, Yu et al reported that small
dense LDL particles reduced by 62% but large LDL subclasses did not, and overall LDL particle
size remained unchanged after a triathlon race [229]. In another study, a cross-country run was
associated with changes in the average LDL subfractions [222]. Overall, these limited studies
have given inconsistent results. 
2.5.2 Physical activity, oxidative stress and LDL oxidation
Despite the beneficial effects of regular aerobic physical activity, strenuous aerobic exercise may
increase muscle oxygen flux and free radical generation, which may overcome the antioxidant
defense and induce oxidative stress [230,231]. The anaerobic exercise (at or beyond anaerobic
threshold) may result in an acidic environment that may promote oxygen release from
hemoglobin and enhance oxidative stress [232]. The adaptive response of the antioxidant
systems is important in protecting the body from the free radical attack after the strenuous
exercise [233,234]. The free radical generation during the exercise is followed by the induction
of free radical scavenger enzymes in the skeletal muscle [235,236] and the modulation or
redistribution of the major circulating antioxidants [237-239]. Some studies have shown that an
acute bout of strenuous exercise may activate the antioxidant enzymes [233,235] as well as the
major plasma antioxidants such as α–tocopherol, ascorbic acid, uric acid, and bilirubin [238,240-
243]. Both chronic and regular exercise training seem also to up-regulate antioxidant enzymes in
those tissues actively involved in exercise [233,244,245] as well as the circulating antioxidants
[246]. 
Several studies have reported that athletes or trained subjects have low LDL baseline conjugated
dienes or increased resistance of LDL to in vitro oxidation as compared to untrained controls
[239,243,247]. These results suggested that regular exercise might be favourable. The data on
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the effect of the periodic training programs on LDL oxidation, however, are less consistent. No
changes were observed in LDL susceptibility to oxidation after a 3-month intense physical
training in ever trained marathon runners [248]. In contrast, Vasankari et al reported a reduction
in baseline LDL diene conjugation in sedentary subjects after 10-month exercise program [249].
Pincemail et al observed elevated levels of autoantibodies against oxidized LDL in some, but not
all, athletes after 4 months of competition [250]. 
An increased susceptibility of LDL to oxidation in vitro after an acute endurance exercise has
been observed by several groups [251-254]. These results indicate that endurance physical
activity may be harmful although the antioxidant systems are activated during the acute
endurance exercise. One possible explanation is that a greatly excessive rate of free radical
generation during the endurance exercise exceeds the capacity of the defense system causing a
shift of pro-oxidant/anti-oxidant balance in favor of the former [234,235]. 
2.6 Diabetes, LDL particle size and LDL oxidation, and endothelial dysfunction
2.6.1 Diabetes, LDL particle size and oxidative stress
Type 2 diabetes is associated with a 2- to 4-fold increased risk for CAD [255-257]. The excess
risk for CAD may be in part attributed to insulin resistance, hyperinsulinemia, obesity and
dyslipidemia [258,259]. Dyslipidaemia in type 2 diabetes includes elevated levels of plasma TG,
low levels of HDL, a preponderance of small dense LDL, and increased postprandial lipaemia
[256,260,261]. As expected, the preponderance of small dense LDL has been consistently
reported in type 2 diabetes [84,262,263], since the key determinant of LDL particle size is
plasma TG concentration [257,260,261]. Importantly, small dense LDL is derived from large
VLDL1 particles that are elevated in type 2 diabetic patients [264]. 
Hyperinsulinemia and hyperglycemia may enhance the production of free radicals and induce
oxidative stress [265,266] that may also contribute to increased risk for CAD in diabetes [257].
In diabetes, oxidative stress is caused by both an increased formation of plasma free radicals and
a reduction in antioxidant defenses [266]. Free radical production caused by hyperglycemia may
occur via different routes: nonenzymatic glycation, auto-oxidation of glucose, and intracellular
activation of the polyol pathway [266]. Reduced total antioxidant capacity has been reported in
the patients with type 2 diabetes [267]. In diabetes, oxidative stress may enhance micro- and
macro-vascular diseases by promoting LDL oxidation [257] and platelet activation [268], and
endothelial dysfunction [269-271]. 
2.6.2 Endothelial dysfunction, LDL particle size and LDL oxidation
Endothelium is a monolayer that lines all the blood vessels and it is the largest autocrine,
paracrine, and endocrine organ of the body. The endothelium regulates vessel tone, platelet
activation, monocyte adhesion, thrombogenesis, inflammation, lipid metabolism, and vessel
growth and remodelling [269,272]. Some of these functions of endothelium can be modulated by
endothelium-derived nitric oxide (NO), which is synthesized from L-arginine through the action
of the NADPH-dependent enzyme nitric oxide synthase (NOS) [273]. Impairment of the
synthesis and biological activity of NO has therefore far-reaching consequences for
atherosclerosis and thrombosis. 
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Decreased NO bioactivity has been observed in the patients with CAD as well as in patients with
diabetes, hypercholesterolemia, hyperhomocysteinemia, hypertension, and smoking [273,274].
These disorders are frequently associated with increased oxidative stress, particularly increased
production of superoxide radicals. Potential sources of endothelial-derived superoxide including
xanthine oxidase, cyclooxygenases, NADPH oxidase and leakage from the mitochondrial
respiratory chain, can directly inactivate NO via formation of peroxynitrate (ONOO-) [273].
Some studies have shown that oxidized LDL as well as native LDL can inhibit the synthesis or
release of NO by endothelial cells, or attenuate its biological activity [275,276]. Antioxidants,
however, can diminish the level of superoxide and protect LDL from oxidation [273,277]. Thus
antioxidants may improve endothelium-dependent vasodilation by limiting oxidative stress and
improving the bioactivity of NO [273]. 
Endothelial dysfunction has been found in asymptomatic subjects with increased risk for CAD
[270,278]. The assessment of endothelial function in the forearm vascular bed has been used as a
non-invasive approach to study the pathophysiology of the early atherosclerosis [270] and to
evaluate new or emerging risk factors in atherogenesis [278]. Small dense LDL has been
reported to be associated with endothelial dysfunction in type 1 [279] and type 2 [280] diabetic
patients as well as in healthy subjects [281] in some, but not in all [282,283] studies. The data on
the association between endothelial dysfunction and susceptibility of LDL to oxidation in vitro
[279,284], or autoantibodies against oxidized LDL [285,286] are also inconsistent. 
2.7 Clinical characteristics and genetics of Familial combined hyperlipidemia (FCHL)
Familial combined hyperlipidemia (FCHL) is the most common familial lipid disorder and is
responsible for more than 10% of premature CAD. This disease was first characterised in 1973
by Nikkilä and Aro [287] who analysed 101 patients with previous myocardial infarction (MI)
under 50 years of age. The lipid status was evaluated in 24 of the 101 families. The authors
found that half of family members were hyperlipidemic with different lipid phenotypes, i.e.
multiple type hyperlipidemia. In the same year, similar dyslipidemia was also reported
independently by two American groups [288,289] and was named as “familial combined
hyperlipidemia” by Goldstein et al [288]. The population prevalence of FCHL is about 0.3-2.0%
[288,290]. 
The diagnosis of FCHL is typically based on the index subject with premature CAD and the
presence of different lipid phenotypes, such as elevated levels of plasma TC (Fredrickson
phenotype IIA), TG (IV) or both (IIB), in affected first-degree relatives [287-290]. The lipid cut-
off points used to define the phenotypes usually utilize age and gender-specific 90th or 95th
population percentiles of TC or TG [291,292]. In some studies, the definition has been based
only on reference values of TC and TG [293-295]. The existence of premature CAD in the
family is also required for the diagnosis of FCHL in addition to the lipid criteria [292-294].
Recently, a criterion of using plasma levels of TG and apoB (hypertriglyceridemia and
hyperapolipoprotein B-100) has been proposed [296]. However, the metabolic and CAD
predictive power of the new criteria must be validated in clinical trials of different FCHL
populations as well as in genetic studies before it can be accepted. 
2.7.1 Defects of lipoprotein metabolism in FCHL
Available evidence indicates that FCHL is a metabolically and genetically heterogeneous
disorder [297,298]. In general, the lipoprotein profile in FCHL patients is characterized by
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increased concentration of apoB-containing VLDL and LDL, preponderance of small dense LDL
and lower levels of HDL cholesterol, insulin resistance and/or impaired fatty acid metabolism
[290,299,300].  
               
FCHL is considered to be caused by an increased hepatic production of VLDL or LDL, with or
without impaired clearance of triglyceride-rich lipoproteins [300,301]. Although apoB
overproduction is a well-established feature of FCHL, the underlying mechanism is unclear
[290,293,302]. A high level of apoB is also a characteristic feature of hyperapobeta-
lipoproteinemia (hyperapoB), which was initially applied to the conditions with increased
protein but normal cholesterol levels in plasma low density (beta) lipoproteins [303]. As
hyperapoB also predisposes patients to premature CAD [303,304] and aggregates in families
[305,306], it is still unclear whether they are two distinct entities or two overlapping syndromes
[290,307]. 
 
Several studies have shown that the clearance of CM and CM remnant is delayed, resulting in
postprandial hyperlipaemia in FCHL [308,309]. Thus, the prolonged postprandial hyperlipemia
further aggravates the elevation of TG-rich lipoprotein particles in FCHL patients [310].
In FCHL, LDL particles appear to be heterogeneous in their physical and chemical properties,
with a predominance of small, dense LDL particles [311]. This feature of dyslipidemia in FCHL
has been confirmed by several investigators [291,299,312,313]. Small dense LDL is particularly
prevalent in phenotype IIB and IV FCHL subjects. Some data have shown that LDL particle size
is also smaller in phenotype IIA subjects than in their non-affected relatives [291,297,314].
Interestingly, small dense LDL in FCHL patients persisted despite substantial reductions in
plasma TG after treatment with gemfibrozil [299]. These data suggest that there is a familial
contribution to LDL subfraction distribution in FCHL. Whether small dense LDL in FCHL is an
inherent feature of genetically determined FCHL trait or a consequence of lipid abnormalities
still remains a debated question [291,313,314]. Bredie et al estimated that serum lipid and
lipoprotein concentrations might explain approximately 60% of the variation of the LDL particle
profile [291]. Segregation analysis has suggested that the small dense LDL trait in FCHL is
determined by a major gene and an additional polygenic component [291,312]. However, the
gene(s) that may contribute to decreases in LDL particle size also contribute significantly to
higher plasma levels of TG and lower plasma levels of HDL cholesterol [315]. Recently
Vakkilainen et al reported that HL and CETP activities are associated with LDL particle size in
FCHL even after adjustment for plasma TG [316]. In addition, the prolonged residence time of
VLDL1 particles in circulation may also favor the formation of small dense LDL in FCHL [71]. 
Low levels of HDL cholesterol are commonly found in FCHL, especially in subjects with
hypertriglyceridemia [290,297]. Increased TG concentrations, small dense LDL particles and
low HDL cholesterol concentrations, so called lipid triad [317], is a common feature of the
dyslipidemia in FCHL [26,80]. The high prevalence of low HDL cholesterol and small dense
LDL in FCHL is explained by the increase in TG-rich lipoproteins [26,317]. Recently Soro and
co-workers conducted genome scans for low serum HDL concentrations in 25 well-defined
Finnish low HDL families and 29 Finnish FCHL families [318]. From the pooled data analysis
for both low HDL and FCHL families, they found that three loci are potentially important for the
regulation of the HDL cholesterol levels, on chromosomes 8q23, 16q24.1-24.2 and 20q13.11
[318]. These data suggested a partially shared genetic background for the low HDL cholesterol
and FCHL traits [318]. 
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2.7.2 Genetics of FCHL
When FCHL was identified in 1973, Goldstein et al suggested transmission of the genetic trait
by a single, autosomal dominant gene [319], whereas Nikkilä and Aro proposed a heterogeneous
origin for the disorder [287]. Initially, the familial aggregation of traits (elevated TG and TC
levels) and bimodal distribution of plasma TG levels were taken as evidence of a dominant mode
of inheritance [319]. However, recent evidence indicate that the genetics of FCHL is more
complex [298,320-322], and the disorder is heterogeneous [298]. This issue was already
recognized by Nikkilä and Aro three decades ago [287]. It is possible that the complex FCHL
phenotype results from a defect in multiple genes or, alternatively, that the disorder results from
one or more major genes and gene-environment interactions. 
Genome scans of Finnish FCHL families by Pajukanta and co-workers have revealed a novel
gene for FCHL on chromosome 1q21-q23 [320]. The linkage to chromosome 1q was confirmed
later in Chinese, German and American FCHL families [321,323]. These data provide strong
evidence that the region 1q, particularly 1q21-q23, may harbor a strong candidate gene for
FCHL. In addition, a novel FCHL locus on chromosome 11 was reported by Aouizerat et al in
the Dutch FCHL families [322]. In addition, Pajukanta et al have also identified four putative
susceptibility loci: on chromosome 10p11.2 and 2q31 for TG trait, on 21q21 for an apoB trait,
and on 10q11.2-10qter for a TC trait [324]. The data suggest that these new loci can modify the
TG, TC and apoB traits and in combination with the FCHL locus on 1q21-q23 may result in the
complex FCHL phenotype [324]. 
Association studies in complex disease are a powerful tool to confirm conceptual or positional
candidate genes that have been chosen based on their biological function or results from linkage
approaches. Up to date, the LPL gene [325], the HL gene [75], the apoAI-CIII-AIV gene cluster
[326], the peroxisome proliferator-activated receptor gamma (PPARγ) gene [327], and the LCAT
locus [328] have been shown to modulate the FCHL phenotype, but these genes are not the
primary cause of FCHL [329]. 
2.8 Ultrasonographic measurement of carotid artery intima-media thickness (IMT)
Recently, a non-invasive approach of ultrasonographically measuring the intima-media thickness
of large artery walls, especially carotid, has been validated to investigate the extent of
atherosclerosis [271,330,331]. This relatively simple, inexpensive and reproducible measurement
is highly feasible, and appears to reflect the changes in the early stage of atherosclerosis
[330,332]. This measurement is now widely used in the clinical research to evaluate new and
novel risk factors in atherogenesis and effects of risk factor modifications in clinical trial [271]. 
2.8.1 Technical aspects of measurement of IMT
Current ultrasound instrumentation with linear transducers ≥ 8 MHz are most capable of
identifying the 2 arterial interfaces (lumen-intima and media-adventitia) necessary for measuring
IMT. The screening examination is performed bilaterally on the extracranial carotid artery
segments. These segments are the distal 1-cm part of the common carotid arteries (CCA), the
carotid bifurcations (CB), and the proximal 1-cm part of the internal carotid artery (ICA) (Figure
3A) [332]. 
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The validity of the far-wall IMT measurements has been established by comparing the IMT
image obtained by ultrasonography with the IMT determined by microscopy in pathological
evaluation [330,333]. Since the tissue interface has a sufficient difference in acoustic impedance
that produces an echo, the IMT ultrasound image in the near-wall does not always correspond
reliably to any anatomical structure (Figure 3B and 3C) [334]. The validity of near-wall IMT can
therefore be debated. However, Furberg et al pointed out that even if there is a small systematic
difference between the near- and far-wall measurements, the annual IMT progression rates do
not differ between the near- and far-wall [335]. Moreover, including near-wall measurements
may reduce the variability of the outcomes [335]. 
Figure 3. Illustration for carotid-IMT measurement. A. Anatomy of carotid artery. NW, near
wall; FW, far wall. Numbers indicate the acoustic interfaces as follows: 1. Periadventitia-
adventitia, 2. Adventitia-media, 3. Intima-lumen, 4. Lumen-intima, 5. Media-adventitia, 6.
Adventitia-periadventitia. B. Schematic illustration of anatomical (left) correlates of the echoes
seen in B-mode ultrasound images (right). C. B-mode image of the carotid artery.  NW IMT,
between 1 and 2 echogenic lines. FW IMT, between 3 and 4 echogenic lines. (Figures A and B
are adapted from Dr. Kati Ylitalo’s thesis. 
One commonly used method is to restrict IMT measurement to the far-wall of a single segment
(Figure 3C) [334], like the distal segment of the CCA [271]. This superficial and straight
segment offers the best geometric conditions for obtaining a high precision and reproducibility
rate of ultrasound IMT measurement. However, the CCA is less likely to have intrusive
atherosclerotic plaque than the CB and ICA segments (Figure 3A), the CCA may therefore be
not the most appropriate segment to study if the objective is focused on atherosclerosis [271]. 
Another commonly used method is the multiple-sites measurement. This approach usually
consists of measuring IMT in the near- and far-walls of the three main segments of extracranial
carotid arteries (CCA, CB and ICA) on both sides [271]. This approach frequently incorporates
plaque thickness because plaques are common in the CB and ICA of subjects with increased risk
for CAD. This explains why the measured IMT can be considered as a marker of early carotid
artherosclerosis [271]. 
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Several pathological studies have demonstrated that increases in intimal thickness
(fibromuscular hyperplasia) are associated with aging and that medial thickness (smooth muscle
hypertrophy) is associated with hypertension, even in the absence of atherosclerotic plaque
[271,332]. The ultrasonography cannot distinguish between intimal thickness and medial
thickness in the IMT measurement because of insufficient axial resolution [271]. 
2.8.2 Carotid IMT and cardiovascular disease
Atherosclerosis is a process that usually affects all parts of the arterial tree. The degree of carotid
atherosclerosis may be associated with cardio- and cerebro-vascular disease. Several large-scale
prospective studies, like KIHD [336], ARIC [337], CHS [338], CLAS [339] and the Rotterdam
Study [340], have demonstrated that carotid IMT is associated with the incidence of new
myocardial infarction and stroke in asymptomatic subjects at the baseline. These data suggested
that carotid IMT is a strong predictor of the progression of cardio- and cerebro-vascular diseases.
Moreover, carotid IMT is associated with coronary angiographic measures [341-343]. However,
the predictive power appears less strong for IMT measured only in the CCA than for IMT
measured at multiple carotid sites [271,332]. 
In addition, a close relationship of IMT has been observed with a number of cardiovascular risk
factors. Traditional risk factors, such as male gender, ageing, smoking, obesity, blood pressure,
serum total cholesterol levels, and diabetes, are positively associated with carotid IMT in
observational and epidemiological studies in patients at high cardiovascular risk as well as in the
general population [271,344]. In some studies, serum HDL cholesterol was negatively associated
with carotid IMT [345]. 
Some novel risk factors, such as hyperhomocysteinemia [346,347], C-reactive protein (CRP)
[344,348], plasma fibrinogen concentration [349], and plasma viscosity have also been reported
to be associated with carotid IMT. Moreover, a significant association between LDL particle size
and carotid IMT was reported in subjects with insulin resistance [350], and in middle-aged
healthy subjects [351,352], but not in subjects with hypercholesterolemia [353,354]. Likewise,
the data on the associations between carotid IMT and circulating oxidized LDL or autoantibodies
against oxidized-LDL [136,355-357], and susceptibility of LDL to oxidation in vitro [356,358-
360] are inconsistent. 
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3. AIMS OF THE STUDY
Over the last decade, small dense LDL and oxidative modification of LDL have been related to
the development of atherosclerosis. However, the exact mechanisms behind these associations
are still unclear. The present studies aimd to examine the interrelationships between LDL size
and susceptibility of LDL to oxidation in vitro in certain physiological condition (exercise) or
metabolic disorders (type 2 diabetes and FCHL) known to influence oxidative stress and/or to be
associated with excess atherosclerosis (type 2 diabetes and FCHL). These studies aim
specifically answer to the following questions:   
1. How does the physical activity, especially a single bout strenuous aerobic exercise, influence
circulating antioxidants, susceptibility of LDL to oxidation in vitro and LDL particle size?
 
2. Is there any relationship between endothelial dysfunction and LDL particle size, circulating
antioxidants and susceptibility of LDL to oxidation in vitro in type 2 diabetes?
 
3. How does the lipid phenotype of FCHL influence the susceptibility of LDL to oxidation in
vitro? What are the determinants of the susceptibility of LDL to oxidation in vitro in different
lipid phenotypes of FCHL subjects?
 
4. Does small dense LDL and LDL oxidation play any role(s) in the development of early
atherosclerosis? Are there any associations between carotid IMT and LDL particle size and
susceptibility of LDL to oxidation in vitro in asymptomatic FCHL?
 
5. HDL-bound PON1 is believed to protect LDL from oxidative modification. How does this
enzyme protect HDL from CuSO4-induced oxidation in vitro? Are there any associations
between HDL oxidation parameters and PON1 and PON1 gene polymorphisms in FCHL family
members?
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4. SUBJECTS AND METHODS
4.1 Study subjects
Each subject recruited in these studies gave their informed consent to the research protocols,
which were approved by the Ethical Committee of the Minerva Foundation for Medical
Research or Helsinki University Central Hospital. Table 4 outlines the subject characteristics. 
Table 4. Characteristics of the study subjects
M/F
(n)
Age
(years)
BMI
(kg/m2)
TC
(mmol/l)
TG
(mmol/l)
ApoB
(mg/dl)
Study I
   Marathon runners 11/0 31±3 23.3±1.0 3.96±0.40 0.92±0.14 -
   Untrained subjects 10/0 33±3 24.9±0.6 4.76±0.25 1.05±0.09 -
Study II
   Type 2 diabetics 30/0 51±1 27.8±0.4 5.38±0.20 2.22±0.36 120±8
   Normal subjects 12/0 51±1 27.1±0.6 5.69±0.23 1.27±0.18 112±6
Study III
   Affected FCHL 
     Phenotype IIA 10/10 45.7±2.4 26.2±1.2 7.06±0.22 1.68±0.14 118.4±4.5
     Phenotype IIB 11/13 43.3±2.8 26.5±0.6 6.85±0.24 2.83±0.36 129.6±6.0
     Phenotype IV 6/9 33.7±2.9 27.0±0.8 5.37±0.18 2.40±0.19 101.7±8.6
   Non-affected 19/20 35.8±2.2 24.6±0.6 4.98±0.13 1.08±0.06 86.4±3.0
   Healthy spouses 15/15 45.6±1.6 25.1±0.7 5.38±0.13 1.20±0.13 91.6±3.6
Study IV
   FCHL family    
   members 54/94
39.6 
(19.5-67.2)
25.1 
(17.4-40.2)
5.77 
(3.10-9.81)
1.31 
(0.55-11.81)
99.0 
(50.0-260.0)
Study V
   FCHL family    
   members 56/94
39.6
(19.5,67.2)
25.1
(17.4,40.2)
5.76
(3.10,9.81)
1.32
(0.55,11.80)
99.0
(50.0,260.0)
     Affected FCHL 29/46 40.4±1.3 26.5±0.5 6.40±0.13 2.18±0.21 119.3±3.6
     Non-affected 27/48 40.1±1.2 24.7±0.4 5.20±0.09 1.13±0.05 84.5±2.5
M/F, male/female. Data are mean±SEM except for the combined groups of FCHL family
members, which are shown as median and range. 
Study I. Eleven healthy male marathon runners participating in the Helsinki City Marathon were
studied. The subjects ran a full marathon (42.2 km), except for one subject who interrupted the
race after 81 min (16 km). The running times varied from 3.13 to 5.52 hours. The subjects had
no dietary restrictions during the days before the marathon. The information regarding the
energy and nutrient intakes 24 hours preceding the marathon, and liquid nutrient intakes and the
mean energy consumption during the race were required and calculated for each runner. Venous
blood samples were collected from each runner before, immediately after, and 4 days after the
race. To avoid interassay variation, the susceptibility of LDL to oxidation in vitro, TRAP and
measurement of LDL peak particle diameter were analyzed in the samples of each subject from
different time points at the same run of the experiments. In addition, data of marathon runners at
the baseline were compared to those of an age, sex and weight matched healthy control group
(n=10) of untrained subjects. 
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Study II. A total of 30 men with type 2 diabetes and 12 normal men were studied. All
participants were non-smokers. Patients were treated with diet alone (n=18) or with diet plus
sulfonylurea or biguanide preparations (n=12). Drugs were discontinued for 2 days before the
studies to avoid possible confounding effects of the drugs on vascular function [361]. The
subjects with type 2 diabetes did not have symptoms or signs of diabetic nephropathy,
neuropathy or proliferative retinopathy, and no clinical or laboratory evidence of diseases other
than type 2 diabetes. A comprehensive analysis in cardiovascular risk markers including LDL
peak particle diameter, plasma antioxidants and susceptibility of LDL to oxidation in vitro, and
blood flow responses to endothelial-dependent and –independent vasoactive agents were
performed in each participant. 
Studies III, IV and V. All FCHL family members in these studies originally participated in the
EUFAM Study, a European Commission supported multi-center project. The patients were
recruited in Helsinki and Turku University Central Hospitals in Finland. FCHL probands were
selected from patients undergoing elective coronary angiography or from angiography registers.
The inclusion criteria for FCHL probands were: 1) age 30 to 55 for men and 30 to 65 for women;
2) ≥50% stenosis in one or more coronary arteries as assessed by standard coronary angiography,
or clinically verified CAD; 3) serum TC and/or TG ≥ age-sex specific 90th age- and gender-
specific Finnish population percentile; 4) at least 3 accessible first degree relatives; and 5) no
history of type 1 diabetes mellitus, hepatic or renal disease, and no hypothyroidism. Subjects
exceeding the above lipid criteria were coded as affected. Families with at least two affected
family members were included in the final phase of the study (excluding families with lipid
phenotype IIA only). Familial hypercholesterolemia was excluded in each proband using the
lymphocyte culture method [362]. FCHL family members who had lipid medication were
excluded from all of these studies. The TC and TG percentiles utilised in the EUFAM Study for
subjects older than 25 were derived from the FINRISK study performed in Finland in 1992 to
assess the levels of CAD risk factors [363]. For the subjects younger than 25, the Cardiovascular
Risk Factors in Young Finns study was utilised to obtain corresponding fractiles [364].
Calculation of the lipid cut-off points is described in detail by Porkka et al [292]. 
Study III included 59 FCHL subjects with different lipid phenotypes and 39 non-affected family
members from 30 well-defined Finnish FCHL families, and 30 normolipidemic spouses as
healthy controls. LDL peak particle diameter, plasma antioxidants, and susceptibility of LDL to
oxidation in vitro were measured in each participant. 
To conduct the Studies IV and V, 150 (affected=75, non-affected=75) FCHL family members
free of clinical CAD from 38 FCHL families were recruited. Of these 150 FCHL family
members, 35 were also included in the Study III. 
In Study IV, 148 family members (2 non-affected subjects were excluded because of the absence
of carotid IMT data) were studied. In addition to Carotid IMT, LDL peak particle diameter,
susceptibility of LDL to oxidation in vitro, lipid-soluble antioxidants in plasma and in LDL were
determined in this study. 
In Study V, all 150 FCHL family members were studied. Serum ARE and PON1 activities,
PON1 mass concentrations, PON1 genotypes and kinetics of CuSO4-induced HDL oxidation in
vitro were measured.
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4.2 Methods
4.2.1 General biochemical methods 
The biochemical and laboratory test methods used in original publications included in this thesis
are summarized in Table 5. 
Table 5. Biochemical methods used in this thesis
Methods Original publications References
Isolation of plasma lipoproteins I, II, III, IV, V [365,366]
Determination of TC, TG, HDL, apoAI, apoAII, apoB I, II, III, IV, V
Assessment of PL, FC and protein in LDL II, III [367]
Isolation of LDL or HDL for lipoprotein oxidation
measurement
I, II, III, IV, V [199]
[368]
Measurement of α-tocopherol, β-carotene and retinol in
plasma and/or in LDL
I, II, III, IV [369]
Determination of plasma ascorbic acid I, II, III [370]
Determination of plasma thiol groups I, II, III [371]
Determination of plasma uric acid I, II, III
Measurement of plasma glucose and/or HbA1c II, III
Determination of serum free insulin II, III [372]
Determination of serum PON1 mass and activity and
ARE activity, and PON genotypes
V [153,165]
Determination of VO2max, fat free mass and % body fat I
Measurement of hematocrit I
4.2.2 Measurement of LDL or HDL oxidation in vitro
LDL or HDL that contained 1 mg/ml of EDTA was isolated from EDTA plasma for the LDL or
HDL in vitro oxidation experiments. EDTA was removed from LDL by using small dextran-
sulfate affinity columns (Liposorber LA-15, Kaneka, Osaka, Japan) just prior the experiment of
LDL oxidation in vitro in Studies I to III. To simplify the experimental procedure, we set up a
new method in which EDTA was removed from LDL (Study IV) or HDL (Study V) by using
size exclusion chromatography (PD-25 column) just prior the experiment. The new method
allows running 6 samples simultaneously. 
The oxidation of LDL or HDL in vitro was performed by using a modification of the procedure
described by Esterbauer et al. [130]. The pure LDL or HDL solution (100 µg LDL or HDL
protein/ml) was incubated with freshly prepared 10.6 µmol/l CuSO4 (for Studies I to III) in a
total volume of 2 ml. In the literature, the concentrations of CuSO4 used in the LDL oxidation in
vitro varies from 1 to 10 µmol/l, but the most commonly used concentration is 5 µmol/l.
Thereby, we used 5 µmol/l in the experiments for the Studies IV to V. The kinetics of LDL or
HDL oxidation were determined by monitoring the change in absorbance at 27 ºC in a motorized
6-cuvette cell equipped and temperature-controlled Shimadzu spectrophotometer (Shimadzu
UV-1201, Shimadzu, Kyoto, Japan). Absorbance at 234nm was recorded every 2 min. The
change in absorbance over time can be divided into three consecutive phases: lag phase,
propagation phase and decomposition phase (Figure 4) [130]. The lag time (in minutes), the
propagation rate (in nmol/mgLDL or HDL⋅min) and the diene concentration (in nmol/mg⋅LDL
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or HDL) were used as measures of LDL or HDL to oxidation in vitro. The inter-assay coefficient
of variation for lag time was 8.7%. 
Figure 4. Curves of continuous measurement of LDL (A) and HDL (B) oxidation by conjugated
diene absorption at 234 nm (A234nm). 1, lag phase; 2, propagation phase; and 3, decomposition
phase.
4.2.3 Measurement of serum total peroxyl radical-trapping potential (TRAP)
The total peroxyl radical trapping antioxidant potential in human plasma (TRAP) was
determined spectrophotometrically in Studies I to III using a recently validated method [199]. In
this assay, we used DCFH-DA to follow the formation of free radicals during decomposition of
AAPH. Free radicals were formed during thermal decomposition of AAPH in water and
followed by measuring the conversion of DCFH-DA to the highly fluorescent DCF. The DCF
formation was measured at 504 nm in Shimadzu spectrophotometer. Plasma was mixed with
PBS to a final dilution of 1%, followed by addition of DCFH-DA to final concentration of 14
µmol/l. The reaction was initiated by adding AAPH with a final concentration of 56 mmol/l. The
AAPH stock solution was stored at –20 °C, thawed, and kept in ice until added to the incubation.
Trolox, a water-soluble α-tocopherol analogue (8.4 µmol/l), was used as an internal standard and
it was added during the propagation phase when the absorbance had increased to 0.25-0.45. DCF
fluorescence or absorbance formation contains four phases (Figure 5).
The first lag phase (Tserum) is due to the antioxidants in the sample. After their consumption by
free radicals formed from AAPH, the reaction proceeds to the first propagation phase. The
second lag phase (TTrolox), which interrupts this propagation, is due to the addition of the internal
standard, Trolox, to the incubation, and in accordance, the second propagation of the reaction
follows the consumption of the Trolox. Each Trolox molecule is able to neutralize 2 molecules
of peroxyl radicals and the measured TRAP (TRAPmea) can be calculated by comparing the lag
phase caused by serum sample with that caused by a known amount of Trolox: TRAPmea=
(Tserum/TTrolox) × serum dilution factor × 2 × [Trolox] [198]. A theoretical calculated TRAP value
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(TRAPcalc) can be estimated by using the stoichiometric values for antioxidants after the
measurement of their concentrations in human samples. In the Studies I to III, the TRAPcalc was
calculated from four main contributors of plasma antioxidant capacity, e.g. α-tocopherol,
ascorbic acid, thiol groups and uric acid. TRAPcalc= 2.0 × [α-tocopherol] + 1.7 × [ascorbic acid]
+ 0.44 × [thiol groups] + 1.3 × [uric acid] [198]. The difference between TRAPmea and TRAPcalc
(TRAPunknown), which is due to antioxidants that are still unknown or to the synergism among the
various antioxidants present in the plasma, was also calculated in Study I. 
Figure 5. Curves of continuous measurement of serum or plasma TRAP at 504 nm (A504nm).  
4.2.4 Determination of LDL peak particle diameter with gradient gel electrophoresis
LDL peak particle diameter was determined in Studies I to IV using gradient gel electrophoresis on
a linear 1-mm thick gel with 2-10% polyacrylamide [281,373,374]. The vertical slab gels were run
in the Bio-Rad Mini-Protean II Electrophoresis Cell in a cooled room at +4 ºC. Pre-electrophoresis
(20 min at 30 V) and electrophoresis (18 hours 125 V) were performed by using Tris-Glycine buffer
pH 8.3 (0.024 mol/l Tris and 0.192 mol/l Glycine). Serum samples were diluted with sample buffer
containing 0.6 mol/l Tris pH 8.3, 8% sucrose and 0.035% bromphenol blue. Then, 10 µl of diluted
sample was applied to each well. Gels were stained with newly filtered Sudan Black B lipid stain
(0.3% Sudan Black B and 1% Zn-acetate in 30% methanol, 30% 2-propanol) for one hour and
destained with 30% 2-propanol for 24 hours. Gels were kept in 5% acetic acid for 4-6 hours and
dried with Bio-Rad's Gel Air Drying System for 4 hours. 
Gels were scanned with a computer-assisted laser scanning densitometer (Personal Densitometer,
Molecular Dynamics, Sunnyvale, CA) in Studies I to III, or with a Kodak Digital Science DC120
camera and analyzed with a Kodak Digital Science Electrophoresis Documentation and Analysis
System 120 in Study IV. Two isolated LDL samples, which were used as size references and one
control sample were applied on each gel [281,373]. The particle sizes of the two reference LDL
samples were measured by electro-microscopy. The median of the LDL particle diameters was
calculated by measuring diameters of at least 100 LDL particles from the electro-microscopy
photograph. The calculated median diameters of the LDL standards were 27.9 and 23.9 nm. The
mean particle diameter of the major LDL peak (LDL peak particle diameter) was determined by
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comparing the mobility of the sample to the mobility of the calibrated LDL preparation run on each
gel. Coefficient of variation for the inter-gel precision of the used control sample was 1.4-1.8%.
4.2.5 In vivo endothelial function test 
In vivo endothelial function test was performed (Study II) as previously described [375]. Briefly,
after a 10-12 hrs overnight fast, a 27-G unmounted steel cannula (Coopers Needle Works,
Birmingham, UK) was inserted into the left brachial artery. Drugs were infused at a constant rate
of 1 ml/min with infusion pumps (Braun AG, Mesungen, Germany and Harvard Apparatus
model 22, South Natic, MA). Subjects rested supine in a quiet environment for 30 min after
needle placement before any blood flow measurements. Normal saline was first infused for 18
min. Drugs were then infused in the following sequence: SNP (Roche, Basel, Switzerland) at 3
and 10 µg/min; ACh (Iolab Corporation, Claremont, CA) at 7.5 and 15 µg/min; and co-infusion
of NG-monomethyl-L-arginine (L-NMMA) (Clinalfa AG, Switzerland) at a rate of 4 µmol/min
with ACh at rate of 7.5 and 15 µg/min. Each dose was infused for 6 min, and the infusion of
each drug was separated by infusion of normal saline for 18 min, during which blood flow
returned to basal values. Forearm blood flow was recorded for 10 s at 15-s intervals during the
last 3 min of each drug and saline infusion period with mercury-in-rubber strain-gauge venous
occlusion plethysmography (EC 4 Strain Gauge Plethysmograph, Hokanson, Bellevue, WA)
combined with a rapid cuff inflator (E 20, Hokanson), an analog-to-digital converter (McLab/4e,
AD Instruments, Castle Hill, Australia) and a personal computer, as previously described [375].
The measurement was performed simultaneously in the experimental and control arm. The mean
of the final five measurements of each recording period was used for analysis.
4.2.6 Ultrasonographic measurement of carotid artery IMT
Ultrasound scannings were performed in Study IV with a Hewlett-Packard Image Point M2410A
ultrasound system (Hewlett-Packard, Andover, Mass.) equipped with a 10 MHz linear array
transducer and videotaped with a Panasonic AG-MD830E PAL S-VHS VCR. One physician
carried out all ultrasound examinations. Longitudinal images from three projections
(anterolateral, lateral, and posterolateral) were displayed for the common carotid artery (CCA),
carotid bulb (CB) and internal carotid artery (ICA). Measurements were carried out at a total of
28 sites, both the far wall and the near wall of six arterial segments: right and left distal 1 cm of
CCA, CB, and proximal 1 cm of ICA. All three projections in CCA and CB, and a single angle
in ICA with the best visibility were used. 
IMT measurements were done by a single observer at Oy Jurilab Ltd (www.jurilab.com) with a
computerized reading system using the Prosound software (Caltech, Pasadena, CA) and a video
frame grabber. IMT measurements from videotapes were made at a total of 28 sites
corresponding to the 28 sites where the scanning was focused. The mean, maximum and
minimum IMT were derived from each measurement. The average of all mean IMT
measurements over 28 (or fewer) sites was chosen as the outcome variable. 
4.2.7 Statistical analyses
Statistical analyses were performed with SYSTAT statistical package (SYSTAT, Inc. Evanston, IL,
USA) in Studies I and II, or with SPSS statistical package in Studies III to V. All data are expressed
as mean±SEM. Variables with non-normal distribution were log10 transformed. P-values less than
0.05 were considered as statistically significant. 
40
In Study I, the multiple comparisons among the repeated observations measured before, immediately
after and 4 days after the race were tested by one way repeated measures ANOVA. When the overall
model proved statistical significance (p<0.05), the differences between the observations at different
time points were tested by Bonferroni t-test. Comparisons between two groups were conducted
using unpaired Student’s t-test (Studies I to II). In Studies III to V, data among the different groups
were tested by two-way ANOVA in which FCHL family number (which indicates that the subject
belongs to a certain family) was used as a random factor to, at least in part, correct for the
dependence of the study subjects. If the differences existed among the means, the post hoc tests were
performed with Tukey HSD multiple comparison test (Study III). Covariance analyses (ANCOVA)
were used to adjust for differences between groups in age, BMI and gender (Study III). The
frequency distribution of the categorical variables between 2 groups was compared with X2 test
(Studies IV and V). 
Pearson correlation analyses were used to show association between variables, which were
distributed normally. Spearman’s rank correlation analyses were performed if variables were not
normally distributed. Correlation analyses in Studies IV and V were tested by multivariate
analysis with FCHL familial number as an independent variable. The predictors for the
subsequent multivariate analyses were selected on the basis of the correlation analyses (P<0.20
when adjusted only for family number). Multiple stepwise (backward) regression analyses were
performed to estimate the independent determinants of lag time for LDL oxidation and carotid
mean IMT (Study IV) and HDL oxidation parameters (Study V). 
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5. RESULTS
5.1 Effects of a marathon run on LDL particle size, LDL oxidation, and serum TRAP
(Study I)
Before the marathon run, the runners had increased plasma HDL and TRAPmea concentrations
and decreased susceptibility of LDL to oxidation in vitro as compared to a group of sedentary
male subjects. However, other variables were comparable between the two groups (Table 6).
Plasma lipids and lipoproteins were comparable in marathon runners before, immediately after
and 4 days after the race (Table 4 in original publication I). In addition, the LDL peak particle
diameter was similar among the different time points before and after the marathon run (Table 7
and Figure 6A).  
Immediately after the race, plasma TRAPmea, TRAPcalc (Figures 6C and 6D), TRAPunknown and
plasma uric acid were significantly increased as compared to the baseline values before the race.
Notably the plasma ascorbic acid, α–tocopherol, β-carotene and retinol levels remained
unchanged, but plasma levels of thiol groups reduced (Figure 7). The plasma TRAPmea and
TRAPunknown values remained elevated for at least 4 days after the race, although the values 4
days after the race were lower than those immediately after the race (Figure 7). TRAPcalc and
individual plasma antioxidants 4 days after the race were comparable to baseline values before
the race (Figures 6D and 7). 
As shown in Table 7 and Figure 6B, the susceptibility of LDL to oxidation in vitro was
significantly increased immediately after and 4 days after the marathon race in each runner. The
rate of oxidation measured as the rate of propagation was also significantly increased
immediately after the race (Table 7), but this change was abolished 4 days after the race. No
significant differences were observed in the concentrations of diene formation during LDL
oxidation, α–tocopherol, β-carotene or retinol in LDL after the race as compared to baseline
values (Table 7). 
Table 6. Clinical characteristics, lipids, lag time and antioxidants in sedentary subjects and   
marathon runners before the marathon run
Marathon Runners Sedentary Subjects Unpaired  t test
N = 11 N = 10 P value
Age (years) 31.1±2.7 32.6±2.9 NS
Body mass index (kg/m²) 23.3±1.0 24.9±0.6 NS
Triglycerides (mmol/l) 0.92±0.14 1.05±0.08 NS
Total Cholesterol (mmol/l) 3.96±0.40 4.76±0.25 NS
LDL-C (mmol/l) 2.46±0.23 3.06±0.24 NS
HDL-C (mmol/l) 1.52±0.10 1.25±0.04 <0.05
Lag Time (min) 180.2±6.6 155.5±9,9 <0.05
TRAPmea (µmol/l) 1071.5±59.6 864.3±79.8 <0.05
Ascorbic acid (µmol/l) 86.2±9.8 62.6±7.6 NS
α-Tocopherol (µmol/l) 17.5±1.9 21.9±1.7 NS
Thiol groups (µmol/l) 361.7±14.8 330.6±11.7 NS
Uric Acid (µmol/l) 294.9±16.4 336.0±12.4 NS
Data are Mean±SEM. Statistical comparisons were tested by unpaired student's t test.
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Table 7. Conjugated dienes formation, lipid-soluble antioxidants in LDL and LDL peak particle
diameter of subjects before, immediately after and 4 days after the marathon run
Before
Immediately
after 4 days after
P value
(ANOVA)
LDL oxidation
Lag time (min)
Diene (mmol/mgLDL)
Rate (nmol/mgLDL⋅min)
180±7
475.2±20.7
3.87±0.24
152±4***
477.3±14.1
4.68±0.23*
155±7***
487.3±23.9
4.31±0.27
<0.001
NS
<0.05
Antioxidants in LDL (nmol/mgLDL)
α-Tocopherol in LDL 
β-Carotene in LDL 
Retinol in LDL 
10.1±0.9
0.78±0.10
0.06±0.00
10.8±1.0
0.77±0.07
0.06±0.00
11.0±1.1
0.73±0.10
0.063±0.00
NS
NS
NS
LDL peak particle diameter (nm) 27.1±0.3 27.5±0.3 27.2±0.2 NS
The values are mean±SEM. Statistical comparisons among repeated measures of subjects were
tested by one way ANOVA for repeated measures followed by Bonferoni t test. *P<0.05 and
***P<0.001 gives statistical significance for comparison with values before the marathon.
Figure 6. Effects of marathon race on LDL peak particle diameter (A), lag time (min) of diene
formation during LDL oxidation in vitro (B), measured trapping antioxidant capacity of plasma
(TRAPmea, C), and calculated TRAP (TRAPcalc, D). Values before, immediately after, and 4 days
after the race of each marathon runner (n=11) are presented. Presented values of TRAPmea and
TRAPcalc immediately after the race are the corrected values according to the plasma volume
shifts.
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Figure 7. Measured (TRAPmea), calculated (TRAPcalc) and unknown (TRAPunknown) total
peroxyl radical trapping capacity, and antioxidant properties of 4 main circulating antioxidants
of the marathon runners before, immediately after (corrected for plasma volume shifts) and 4
days after the marathon run. The antioxidant capacities of each antioxidant were calculated by
multiplying its plasma concentration by the stoichiometric value (molar amount of free radicals
trapped by mole of each antioxidant). *p Before vs Immediately after, ¤p Immediately after vs 4
days after, †p Before vs 4 days after. *p < 0.05, **p < 0.01, ***p < 0.001.
5.2 Relationship between endothelial dysfunction and LDL particle size, LDL oxidation
and serum TRAP in type 2 diabetes (Study II)
In Study II, basal blood flows in the patients with type 2 diabetes were insignificantly lower than
in non-diabetic control subjects throughout the endothelial function test (Figure 8). Blood flow
was slightly lower during the low-dose infusion of ACh, but significantly lower during the high-
dose ACh infusion, in the patients with type 2 diabetes (6.1±0.5 ml/dl⋅min) than in normal
subjects (9.7±1.5 ml/dl⋅min, P<0.01). Blood flows were comparable between the groups during
the low- or high-dose SNP infusion (Figure 8). The ratio of blood flows during infusion of the
high dose of ACh to that during infusion of the high dose of SNP was significantly lower in the
patients with type 2 diabetes (0.7±0.05) than in normal subjects (1.10±0.18, p<0.01). The
corresponding blood flows during co-infusion of L-NMMA with low- or high-dose of ACh were
comparable in the patients with type 2 diabetes and normal subjects (Figure 8). Thus when the
nitric oxide (NO)-dependent component of ACh-stimulated blood flow was abolished, blood
flows were similar between the patients with type 2 diabetes and normal subjects. The percent
inhibition of ACh stimulated blood flow by L-NMMA was significantly lower in the patients
with type 2 diabetes (21±5%) than in normal subjects (45±7%, P <0.05). 
In Study II, type 2 diabetic patients had increased plasma TG and reduced LDL peak particle
diameter as compared to the control subjects. Both TRAPmea and TRAPcalc were comparable
between the study groups despite the increased plasma thiol groups and reduced β-carotene
levels in type 2 diabetic patients as compared to the control subjects. In addition, plasma uric
acid, ascorbate, α-tocopherol and retinol were comparable between the study groups. The lag
times for LDL oxidation in vitro were also similar for both groups (Table 8). In correlation
analysis, only LDL peak particle diameter was significantly correlated with endothelium-
dependent vasodilation in the patients with type 2 diabetes. However, the lag time for LDL
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oxidation, serum lipid variables, glucose and HbA1c did not correlate with endothelium-
dependent vasodilation in these patients (Figure 3 in original publication II). 
Figure 8. Mean ± SEM blood flows in the experimental and control forearm and the ratio
(insert) of blood flows during infusion of a high dose of ACh to that during infusion of a high
dose of SNP in normal subjects and in patients with type 2 diabetes. SNP was infused at rate of 3
(18-24 min, low dose) and 10 (24-30 min, high dose) µg/min. ACh was infused at rates of 7.5
(48-54 min, low dose) and 15 (54-60 min, high dose) µg/min. L-NMMA (4umol/min) was infused
with ACH at rates of 7.5 (84-90 min) and 15 (90-96 min) µg/min. **P<0.01 for patients with
type 2 diabetes versus normal subjects. 
Table 8. Serum lipid and lipoproteins, plasma TRAP and antioxidants, LDL peak particle
diameter and susceptibility of LDL to oxidation
Type 2 diabetic subjects
N=30
Normal control subjects
N=12
Total cholesterol (mmol/l) 5.38±0.20 5.69±0.23
Triglycerides (mmol/l) 2.22±0.36* 1.27±0.18
LDL cholesterol (mmol/l) 3.21±0.15* 3.89±0.20
HDL cholesterol (mmol/l) 1.17±0.05 1.23±0.10
TRAPmea (µmol/l) 1034±50 1000±68 
TRAPcalc (µmol/l) 685±22 704±13 
Uric acid (µmol/l) 451±27 455±12
Thiol groups (µmol/l) 161±3** 139±4
Ascorbate (µmol/l) 81±5 93±8
α-Tocopherol (µmol/l) 21±2 18±2
β-Carotene (µmol/l) 0.24±0.02** 0.37±0.05
Retinol (µmol/l) 1.95±0.09 2.17±0.12
LDL lag time (min) 183±7 183±9
LDL peak particle diameter (nm) 26.2±0.2* 26.8±0.2
Data are mean ± SEM. TRAPmea, measured TRAP. TRAPcalc, theoretical calculated TRAP.
*P<0.05, **P<0.01 for type 2 diabetic patients versus normal subjects. 
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5.3 LDL oxidation, antioxidants and antioxidant capacity in FCHL (Studies III and IV)
5.3.1 LDL oxidation in FCHL
In Studies III and IV, FCHL patients, independently of FCHL phenotype, had significantly
reduced lag time for LDL oxidation as compared to healthy spouse controls (Table 9) or non-
affected FCHL family members (Figure 9C). There were no significant differences in the
propagation rate and the amount of conjugated diene formation during LDL oxidation between
the FCHL patients and healthy spouse controls (Table 9). In the Studies III and IV, the contents
of α-tocopherol, β-carotene and retinol in LDL particles were comparable between FCHL
patients and healthy spouse controls (Table 9) or non-affected FCHL family members (results in
original publication IV). 
5.3.2 Antioxidants and antioxidant capacity in FCHL
In Study III, plasma TRAPmea and TRAPcalc tended to be higher in affected FCHL groups than in
healthy spouse controls, but the difference was significant only for phenotype IIB (Table 9).
FCHL patients with IIB and IV phenotypes, but not those with IIA phenotype, had significantly
higher plasma concentrations of uric acid than healthy spouses. The plasma concentrations of
vitamin C and protein-bound thiol groups were however comparable in FCHL patients and
healthy spouse controls (Table 9). Plasma concentrations of α-tocopherol were significantly
higher in FCHL patients than in healthy spouse controls (Table 9) or in non-affected FCHL
family members (results in original publication IV). The plasma concentrations of β-carotene
and retinol were however comparable in FCHL patients and healthy spouse controls (Table 9) or
non-affected FCHL family members (results in original publication IV). 
In Study III, serum urate correlated significantly with BMI (r=0.425 p<0.001), plasma TG
(r=0.413 p<0,001) and fasting insulin concentrations (r=0.407 p<0.001) in the group of all
FCHL family members. There were also significant correlation between plasma α-tocopherol
and TC (r=0.663 p<0.001), LDL-cholesterol (r=0.522 p<0.001) and TG (r=0.512 p<0.001) in the
group of all FCHL family members. The plasma TRAPmea correlated with plasma α-tocopherol
(r=0.344 p<0.01) and urate (r=0.658 p<0.001) in the group of all FCHL family members.
5.3.3 LDL particle size in FCHL
In Studies III and IV, the LDL peak particle diameter was significantly smaller in FCHL patients
than in healthy spouse controls (results in original publication III) or in non-affected group
(Figure 9B). In Study III, we also measured the lipid composition of LDL. The relative
triglyceride content of LDL was significantly higher in FCHL patients than in healthy spouse
controls (6.69±0.26 vs 5.14±0.22 %, p<0.001) or in the non-affected group (6.69±0.26 vs
5.08±0.20 %, p<0.001). These changes were most striking in the FCHL patients with phenotype
IIB and IV. The relative contents of free cholesterol, cholesterol ester, phospholipid and protein
of LDL were comparable among FCHL groups and healthy spouse controls (Table 4 in original
publication III). In Study III, there was an inverse correlation between LDL peak particle
diameter and plasma TG levels in the group of all FCHL family members (r=-0.502, p<0.001)
and in healthy spouse controls  (r=-0.411, p<0.05). LDL peak particle diameter also correlated
negatively with both TG content of LDL (r=-0.368, p<0.05) and apoB (r=-0.501, p<0.001) in the
group of all FCHL family members, but not in healthy spouse controls. 
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Table 9. Conjugated dienes formation and lipid-soluble antioxidants in LDL and plasma TRAP and antioxidants in study subjects
FCHL phenotype
II A IIB IV Non-affected Healthy spouses
Lag time (min)
Maximal dienes (nmol/mgLDL)
Propagation rate (nmol/mgLDL⋅min)
150.2±5.9*
513.4±14.4
4.61±0.34
145.3±4.5†
485.8±12.4
4.29±0.28
149.3±7.6*
493.7±15.1
4.36±0.22
177.9±5.1
491.2±7.8
4.70±0.29
170.9±5.3
474.6±12.1
4.46±0.22
Antioxidants in LDL (nmol/mgLDL-protein)
α-Tocopherol 
β-Carotene 
Retinol 
(n=16)
10.5±0.8
0.45±0.09
0.08±0.03
(n=18)
10.8±0.8
0.33±0.09
0.08±0.02
(n=11)
9.9±0.9
0.31±0.09
0.08±0.03
(n=27)
8.8±0.3
0.31±0.05
0.04±0.01
(n=19)
10.0±0.7
0.54±0.10
0.09±0.02
Plasma TRAPmea (µmol/l) 762±32 831±31* 798±42 716±25 698±23
TRAPcalc (µmol/l) 665±23 731±29* 740±57 626±21 638±17
Plasma vitamin C (µmol/l) 37.6±3.3 38.1±3.2 34.5±4.0 43.8±2.6 44.8±3.6
Plasma thiol groups (µmol/l) 279±11 281±15 306±10 299±9 298±10
Plasma uric acid (µmol/l) 325±15 366±21* 378±39* 290±14 291±10
Plasma α–tocopherol (µmol/l) 33.5±1.3‡ 35.4±1.2‡ 34.1±2.7‡ 26.4±0.8 27.2±1.1
Plasma β–carotene (µmol/l) 0.77±0.16 0.47±0.06 0.40±0.06 0.62±0.09 0.80±0.16
Plasma retinol (µmol/l) 3.12±0.17 3.49±0.22 2.86±0.29 3.13±0.13 3.09±0.16
The values are mean ± SEM. TRAPmea, measured TRAP. TRAPcalc, theoretically calculated TRAP. *P<0.05, †P<0.01, ‡P<0.001 vs 
healthy spouse control.        
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5.3.4 Associations between LDL oxidizability and selected variables in FCHL
Lag time for LDL oxidation was significantly correlated with TC, log TG, apoB, LDL peak
particle diameter (results and Figure 1a in original publication III), pulse pressure, smoking
pack-years, ß-carotene in LDL, and retinol in LDL in FCHL family members (Table 2 in original
publication IV). In the multivariate analysis, LDL peak particle diameter, TC, and α-tocopherol
in LDL were significant predictors of variation in the lag time for LDL oxidation, independently
of logTG, apoB and clinical variables (age, gender, pulse pressure and smoking pack-years)
(Table 2 in original publication IV). 
5.4 Association between carotid IMT and LDL particle size and LDL oxidation in
asymptomatic FCHL family members (Study IV)
In Study IV, carotid mean IMT was comparable in affected and non-affected family members
(0.75±0.02 vs 0.73±0.02 mm, P>0.05; Figure 9A). LDL peak particle diameter was significantly
smaller (26.0±0.2 vs 27.3±0.1 nm, P<0.001; Figure 9B), and the lag time for LDL oxidation was
significantly shorter (106.3±1.4 vs 112.4±1.2 min, P<0.01; Figure 9C) in affected than in non-
affected family members.
In correlation analysis (Table 3 in original publication IV), carotid mean IMT correlated
significantly with age, BMI, SBP, DBP, pulse pressure, smoking pack-years, logTG, TC, LDL-
C, TC/HDL-C ratio, apoB, LDL peak particle diameter, lag time for LDL oxidation, α-
tocopherol, and α-tocopherol in LDL. Correlations with LDL peak particle diameter (r=-0.22,
P=0.008), and lag time for LDL oxidation (r=-0.20, P=0.017) were still significant after the
adjustments for family number, age, BMI and gender. If the analyses were performed in affected
and non-affected subjects separately, carotid mean IMT correlated significantly with LDL peak
particle diameter (r=-0.310, P=0.007) and lag time for LDL oxidation (r=-0.268, P=0.024) in
affected, but not in non-affected family members (Figure 10).
Figure 9. Individual values of carotid mean IMT (A), LDL peak particle diameter (B), and lag
time for LDL oxidation (C) in affected and non-affected asymptomatic FCHL family members.
Horizontal lines represent the group mean. 
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Figure 10. Relationship between carotid mean IMT and LDL peak particle diameter (A) and lag
time for LDL oxidation (B). g affected family members, i non-affected family members. 
Table 10. Multivariate analyses of predictors affecting mean IMT 
Independent variables Model 1 Model 2 Model 3
β P β P β P
Age 0.805 <0.001 0.697 <0.001 0.721 <0.001
Gender (male=1, female=0) 0.171 0.002 0.101 0.035 0.150 0.006
BMI NE NE -0.076 NS
Smoking pack-years NE 0.075 NS 0.058 NS
Pulse pressure 0.263 <0.001 0.199 <0.001
TC/HDL ratio -0.115 NS -0.190 NS
ApoB 0.087 NS 0.171 NS
LDL peak particle diameter -0.108 0.045 -0.199 0.003
LDL lag time -0.090 NS 0.022 NS
α-Tocopherol in LDL 0.182 0.002 NE
β-Carotene in LDL 0.100 NS 0.055 NS
Adjusted R2 0.722 (P<0.001) 0.752 (P<0.001) 0.790 (P<0.001)
β, standardized coefficient. NE, does not enter the final model. Family number was forced into
each model. TC and logTG were tested in models 2 and 3 but did not enter the final models.
Multivariate analysis was used to identify independent determinants of carotid mean IMT (Table
10). In model 1, which included clinical variables, antioxidants in LDL and lag time for LDL
oxidation, mean IMT was independently associated with age, gender and α-tocopherol in LDL,
but not with lag time for LDL oxidation and β-carotene in LDL. In model 2, which included
clinical and lipid variables and LDL peak particle diameter, mean IMT was independently
associated with age, gender, pulse pressure and LDL peak particle diameter. In model 3, which
included all variables from models 1 and 2, age was the strongest independent predictor of the
variation in mean IMT with highest standardized coefficient (0.721, P<0.001), followed by pulse
pressure (0.199, P=0.001), LDL peak particle diameter (-0.199, P=0.003) and gender (0.150,
P=0.006). Lag time for LDL oxidation, however, was not independently associated with mean
IMT. Family number was forced into each model. TC and LogTG were tested in models 2 and 3,
but did not enter the final models. These results indicate that LDL peak particle diameter, but not
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lag time for LDL oxidation, is associated with mean IMT, independently of clinical and lipid
variables.
5.5 Association between paraoxonase-1 and HDL oxidation in FCHL family members (V)
In Study V, Lag time, maximal dienes and propagation rate of HDL oxidation, tended to differ
between the affected and non-affected groups, but the differences did not reach significance. The
absolute serum ARE and PON1 activities, PON1 mass concentrations and specific activities
were comparable in the two groups (Table 2 in original work V). We used the ratios of PON1
parameters to HDL-C as an estimate of the PON1 content per unit weight of HDL. The relative
ratios of ARE/HDL and PON1 mass/HDL were significantly higher in affected family members
than in the non-affected. Therefore there seems to be more PON1 available per unit weight of
HDL-C in affected family members than in the non-affected. In addition, when the data for the
studies IV and V were combined, we found that plasma α–tocopherol concentrations correlated
with PON1 mass concentration (r=0.236, p=0.017) and log PON1 activity (r=0.293, p=0.003).
Likewise, plasma retinol concentrations were significantly correlated with log ARE activity
(r=0.207, p=0.037).
In univariate analyses, serum PON1 mass was significantly associated with maximal dienes and
propagation rate, but not with lag time (Table 11). The correlations between log-transformed
relative ratio of PON1 mass/HDL and maximal dienes and propagation rate of HDL oxidation
were highly significant in both affected and non-affected FCHL family members (Figure 11).
Serum activities of the enzyme were less consistently associated with oxidation parameters. In
addition, oxidation parameters also correlated with PON1 genotypes. Specifically, the maximal
diene formation of HDL oxidation was positively correlated with PON1 55LM (LL=1, LM=2,
MM=3) but negatively correlated with PON1 192QR (QQ=1, QR=2, RR=3) genotypes (Table
10).  
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Figure 11. Relationship between maximal diene formation of HDL oxidation and the log-
transformed ratio of PON1 mass concentrations/HDL in the study subjects (A). Relationship
between propagation rate of HDL oxidation and the log-transformed ratio of PON1 mass
concentrations/HDL in the study subjects (B). g affected subjects, i non-affected subjects. 
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Table 11. Univariate correlation and multivariate regression analyses between parameters for
HDL oxidation in vitro and their potential determinants 
Lag time Maximal dienes Propagation rate
Univariate correlation analysis r P r P r P
Log PON1 activity (U/ml) 0.170 0.060 -0.150 0.099 -0.193 0.032
PON1 mass concentration (µg/ml) 0.036 0.689 -0.198 0.028 -0.195 0.031
PON1 genotype 55LM
(LL=1, LM=2, MM=3)
-0.274 0.004 0.216 0.026 0.254 0.008
PON1 genotype 192QR
(QQ=1, QR=2, RR=3)
0.325 0.001 -0.187 0.053 -0.190 0.050
Multivariate analyses β P β P β P
Log PON1 (U/ml) -0.178 0.294 0.194 0.250 NE -
PON1 mass concentration (µg/ml) -0.290 0.005 -0.230 0.016
PON 1 genotype 55LM
(LL=1, LM=2, MM=3)
-0.147 0.174 NE - -0.082 0.409
PON 1 genotype 192QR
(QQ=1, QR=2, RR=3)
0.309 0.047 -0.174 0.230 -0.039 0.630
r, correlation coefficient adjusted for family number. β, standardized regression coefficient.
ARE, arylesterase; PON1, paraoxonase-1. Family number was forced into each multivariate
model. NE, does not enter the final model. 
Linear regression analyses were used to identify independent associations between HDL
oxidation parameters and other variables in all FCHL family members. Since HDL-C and apoAI
are highly correlated, to avoid multi-collinearity, we did not include both of the two variables in
the same multivariate model. Multivariate analyses revealed that correlations between PON1
mass and oxidation parameters were independent of other factors, including HDL-C (Table 4 in
original work V) and apoAI (not shown). In contrast, the associations between PON1 genotypes
and oxidation parameters tended to be insignificant, except that the Q192R polymorphism
remained associated with lag time (with HDL-C included in the analyses, Table 4 in original
work V) or with maximal diene formation (with apoAI included in the model, not shown).
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6. DISCUSSION 
  
6.1 Evaluation of the methods
6.1.1 Measurement of susceptibility of lipoprotein (LDL or HDL) to oxidation in vitro
In 1989, Esterbauer et al [130] described an in vitro spectrophotometric method for the kinetics
of LDL oxidation in which the CuSO4-induced oxidation of LDL is continuously monitored by
following the formation of conjugated dienes at the wavelength of 234 nm. This in vitro
technique does not measure the presence of oxidation products in the lipoprotein, but provides a
measure of the intrinsic susceptibility (lag time) of the lipoprotein to be oxidized [62]. Since it
can provide reproducible results with unsophisticated equipment, this method has been widely
used in clinical and biochemical research. In some studies, the susceptibility of LDL to oxidation
has been reported to be associated, in a small-scale study, with CAD [10], and in a 3-year
follow-up study, with progression of carotid atherosclerosis [358]. In other studies, susceptibility
of LDL to oxidation was not associated with carotid atherosclerosis [356,360] or was only
marginally associated with the extent of coronary [11] or peripheral [376] atherosclerosis.
This method requires the purification of individual lipoproteins, commonly LDL, and
traditionally it allows running of 6 to 9 samples in an assay. This time-consuming method is thus
inappropriate for use in large-scale population studies. An exposure of the sample to air during
the isolation process of LDL from plasma may also initiate the premature oxidation that may
influence the final results. In addition, experiments are initiated by adding high and non-
physiological concentrations of copper [118]. Hence, some investigators have criticized the
assessment of LDL oxidation in vitro, [377] because the results may be neither biologically nor
pathologically relevant [118]. Although there are some shortcomings, this reproducible method
is still useful to measure the intrinsic susceptibility (lag time) of the lipoprotein to be oxidized,
assuming that the lipoprotein fractions have been properly isolated and treated [62]. Therefore,
the effort to simplify or to improve the method still continues. The use of a 96-well microtiter
plate reader allows a high-throughput measurement simultaneously for multiple samples [378].
In addition, a simple and rapid assessment for susceptibility of lipoprotein to oxidation measured
in the macromolecule fraction of plasma has also been suggested [379].
6.1.2 Assay of serum TRAP
The TRAP assay of Wayner et al [198] was, during the last decade, the most widely used method
for measuring total antioxidant capacity of plasma or serum. In this assay, they used an oxygen
electrode to monitor oxygen consumption during the lipid peroxidation induced by a free radical
generator (AAPH). This is a time-consuming (2 hours per sample) method and not suitable for
large-scale studies. The oxygen electrode cannot maintain its stability over the period of time
required [193]. Valkonen and Kuusi modified the assay to follow the formation of highly
fluorescent DCF that is converted from DCFH-DA by free radicals, with a spectrophotometer
[199]. This method allows us to run 6 to 9 samples in an assay using a spectrophotometer and
has a high reproducibility with a low intra- and inter-assay coefficient of variation (3.4% and
4.6%, respectively). 
TRAP is a sensitive and reliable marker to reflect changes in in vivo oxidative stress, which may
not be detectable through the measurement of single “specific” antioxidants. This method can be
used for evaluating the effect of different treatments on plasma redox status in healthy subjects
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when the results are expressed as a change from the baseline value [197]. The change in TRAP
after treatment may reflect the change of in vivo antioxidant defense status and the effect of the
treatment on the oxidative stress. However, the interpretation of the changes in TRAP depends
upon specific conditions. Patients with chronic renal failure have increased TRAP due to their
increased serum uric acid concentrations. In this situation, an increased antioxidant capacity in
blood is not a desirable condition, but an adaptation to an increased oxidative stress [193]. In
contrast, the decrease in TRAP is not necessarily an undesirable condition if the production of
free radicals decreases [193]. However, in addition to TRAP, it is meaningful to measure plasma
levels of circulating antioxidants, such as vitamins, uric acid, and thiol groups, to get a realistic
view of the redox states in plasma or serum. 
6.1.3 Determination of LDL particle size
   
GGE is a relatively precise and simple method to investigate the LDL and HDL subclasses in
large-scale population studies. This method was originally used to analyze LDL samples. Use of
serum samples in the GGE analyses further simplifies the method. As shown by previous studies,
GGE performed on serum and LDL samples gives closely comparable results [380].
Traditionally two distinct LDL subclasses, i.e., patterns A and B, have been separated by GGE
[8]. In addition, the mean particle size diameter of the major LDL peak has also been used as a
determinant of LDL particle size distribution. When the LDL peak particle diameter is used
instead of separate LDL subclasses, the changes in the overall LDL particle size distribution may
be neglected because the LDL peak particle diameter may remain unchanged despite the
alterations in the concentrations of distinct LDL subclasses. However, no standard system is
available for the separation of LDL subclasses, and consequently the size and density ranges of
the LDL subfractions differ between laboratories. This is the major reason for the use of LDL
peak particle diameter and LDL peak density to characterize LDL distribution in the present
study.  
 
6.2 Effects of endurance aerobic exercise on oxidative stress, LDL oxidation, and LDL
particle size 
 
It has been suggested that strenuous exercise may increase muscle oxygen influx and free radical
generation [230,231]. The body is equipped with an efficient antioxidant defense, and exercise
may enhance the adaptive response of the antioxidant defense system by activating the
antioxidant enzymes [233,234] and major plasma antioxidants [238,240,252] to withstand the
increase in oxidative stress. The present study showed that a marathon run significantly increases
plasma TRAPmea and TRAPcalc as well as certain individual plasma antioxidants immediately
after the race. Notably the TRAPmea remained elevated for at least 4 days after the run. These
results well agree with other published data [240,243,381]. 
Despite the adaptive increase in plasma TRAPmea and plasma uric acid, the lipid-soluble
antioxidants in LDL remained unchanged after the race. In addition, the marathon run increased
the susceptibility of LDL to oxidation in vitro and reduced the lag time for conjugated diene
formation. This change was not a transient phenomenon but persisted over 4 days. The results
are consistent with the published data [251,252,254,381] showing that intensive aerobic exercise
increases LDL oxidation in vitro. 
Several studies have shown that acute endurance exercise does not significantly change the
average concentration of LDL subfractions [222,251] or overall LDL size [229]. Consistent with
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these data, in Study I, LDL peak particle diameter was unaffected by the marathon run. In
addition, we observed no significant change in plasma TG after the race. Since the plasma TG is
the most important determinant of LDL particle size [66,69,317,382], the unchanged LDL size
may be explained by the lack of changes in plasma TG during the exercise. Yu et al reported that
the percentage of small dense LDL particles significantly reduced without a change in large LDL
subclasses during a triathlon race [229]. In contrast, in diabetic patients, physical exercise was
reported to cause a shift of LDL type B to LDL type A [383]. These results suggest that the
effect of exercise on LDL size also depend on the baseline pattern before the exercise. In Study
I, the marathon runners represent ”super active” healthy people who had had a regular training
program for several months before the marathon competition. Their LDL subclass showed a
predominance of large and light LDL particles (LDL peak particle size, 25.5-28.7 nm) before the
marathon run (Figure 3A). It is therefore not surprising that their LDL particle size did not
change after the marathon run.
The degree of LDL oxidation reflects the net effects of its various pro-oxidants and endogeneous
anti-oxidants, LDL particle size [92,93], the concentration of its oxidizable substrates (especially
polyunsaturated fatty acids) in LDL [115,384], and the LDL composition [385]. In our study,
before and after the marathon run, both LDL size and lipid-soluble antioxidants in LDL were
comparable. Kaikkonen et al reported that supplementation of ubiquinol-10 and α–tocopherol
had no effect on lipid peroxidation induced by exhausting exercise [381]. The increased
susceptibility of LDL to oxidation in vitro induced by endurance exercise can therefore not be
explained by the changes in either endogenous lipid-soluble antioxidant in LDL or LDL particle
size. Recently, Benitez et al reported that changes in LDL oxidizability after aerobic exercise are
related to the increase in LDL-associated non-esterified fatty acids (NEFA) [252]. Interestingly,
the endurance exercise significantly elevated the NEFA in LDL and plasma, which is a result of
increased energy requirements and mobilization of triglycerides from adipose tissue [252].
NEFA, associated with the surface of the lipoprotein, can act as a good substrate to initiate
lipoprotein peroxidation [252]. Importantly, free fatty acids seem to be a better substrate for
lipooxygenases than are esterified fatty acids [386]. 
In short, during the prolonged endurance aerobic exercise, the increased generation of free
radicals may exceed the capacity of the defense system, causing a shift in pro-oxidant/anti-
oxidant balance in favor of the former [233,234], despite a simultaneous adaptive increase in
antioxidants [238,240,252]. In general, small amounts of oxidized LDL exist in the circulation
[9,106-108]. The imbalance in pro- and anti-oxidant status may enhance the formation of
circulating oxidized LDL in vivo. Consequently, the amount of pre-formed oxidized LDL rises,
and the presence of pre-formed lipid hydroperoxides in isolated LDL has been known to
influence the oxidative susceptibility of the particle [62,113,119,120]. Therefore, the increased
oxidative stress, increased pre-formed oxidized LDL, and the unchanged antioxidant content in
LDL, together with the change in LDL composition (like increased association of NEFA) [252],
may explain the unexpected increase in the susceptibility of LDL to oxidation in vitro after the
acute, aerobic intensive exercise. 
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6.3 Impaired endothelium-dependent vasodilation in type 2 diabetes and its relation to
LDL particle size, LDL oxidation, and antioxidants
In Study II, vasodilatory responses to the extrinsic NO donor SNP between patients with type 2
diabetes and normal subjects were comparable (Figure 5). These results suggest that the function
of vascular smooth muscle was not impaired in our diabetic patients with a relatively short
duration of disease and with no clinical signs of macrovascular complications. The endothelium-
independent blood flow responses to SNP or glyceryl trinitrate have been reported to be impaired
in type 2 diabetes in some [280,387-389], but not all [390] previous studies. These differing
results may be explained by differences in patient characteristics, such as duration of diabetes or
degree of obesity and hypertension. Importantly, our results confirm the presence of a significant
defect in endothelium-dependent blood flow responses to ACh [280,388,389] and methacholine
[387] in type 2 diabetes. In addition, we co-infused L-NMMA with ACh to evaluate whether the
defect in ACh induced vasodilation in type 2 diabetes was caused by the NO dependent
component of ACh stimulated blood flow. In keeping with previous finding [388], blood flows
were comparable during co-infusion of these drugs. These data imply that the endothelial
dysfunction in our patients was due to a vascular defect specific to the NO pathway [388]. These
data, together with the normal response of vascular smooth muscle to SNP in our Study II and in
previous studies [390,391] and lack of any increase in production of vasoconstrictor prostanoids
in type 2 diabetes [387], imply that neither accelerated NO destruction nor impaired NO action
explains in vivo endothelial dysfunction in type 2 diabetes. Therefore, endothelial dysfunction in
type 2 diabetes is more likely a consequence of a defect in NO production, which may be due to
the decreased NO synthase activity in diabetic patients [392].  
In Study II, LDL peak particle diameter was significantly correlated with endothelial function.
This association has also been reported in type 1 [279] and type 2 [280,393] diabetic patients and
healthy subjects [281] in some, but not all [282,283] previous studies. Increased TG, small dense
LDL and low HDL cholesterol, the so-called lipid triad [317], are commonly seen in type 2
diabetes [255,256] and closely related to each other [26,80]. However, the association analysis in
Study II revealed that among this lipid triad, only LDL size significantly correlated with
endothelial function. Similar results were also reported by Vakkilainen et al in a group of healthy
men [281]. Our results in Study II together with others [279-281] indicated that small dense LDL
may play an important role in endothelial dysfunction, an early event in atherogenesis [394]. The
mechanisms linking small dense LDL to endothelial dysfunction are, however, unclear.
Numerous studies demonstrate that small dense LDL is directly atherogenic; it penetrates into
the extracellular space [21,66] and becomes trapped or retained by binding to arterial
proteoglycans more easily [22]. This process promotes LDL modification in the arterial wall
[22]. Consequently, these particles become more easily oxidized. Modified LDL is able to
initiate several processes that may disturb endothelial function. 
In Study II, the other variables, including lag time of LDL oxidation in vitro, plasma TRAP, and
the major circulating antioxidants, between type 2 diabetic patients and healthy controls were
comparable. No significant correlation appeared between these variables and endothelial
function. Oxidized LDL has been reported to inhibit nitric oxide synthase [395] and
consequently reduce the synthesis of NO and influence endothelium-dependent vasodilation.
However, the available data regarding the association between endothelial dysfunction and
susceptibility of LDL to oxidation in vitro [279,284,393], or autoantibodies against oxidized
LDL [285,286] have given inconsistent results. The differences in the experimental method or
study designs and stages of atherosclerosis may account for the differences in study results. In
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type 2 diabetes, some of the LDL particles may be modified by glucose, glucose oxidation
products, or advanced glycation end-product peptides [396]. In vivo glycation of LDL increases
the oxidizability of the lipoprotein, as also suggested by the correlation between HbA1c and the
susceptibility of LDL to oxidation in vitro in our Study II (Figure 3 in original publication II).
The glycated lipoproteins in type 2 diabetes may also impair endothelial function by mechanisms
independent of LDL oxidizability [396]. 
In some studies in type 2 diabetes, plasma TRAP has been reported to be reduced [267,397,398];
however, further subgrouped analysis revealed that the reduced TRAP was seen only in elderly
diabetic subjects [398,399]. This is in keeping with our results, notably that all of our diabetic
patients were under 60 (51±1). Previous data on individual antioxidants in type 2 diabetes are
highly variable. The inverse correlation between HbA1c and TRAP (Figure 3 in original
publication II) is, however, consistent with previous data [399] and suggests that chronic
hyperglycemia may increase oxidative stress via several mechanisms such as glucose auto-
oxidation or nonenzymatic glycosylation [266]. The comparable TRAPcalc, TRAPmea and major
circulating antioxidants between the type 2 diabetic and normal subjects in Study II imply that
the depletion in circulating antioxidants fails to explain endothelial dysfunction in type 2
diabetes. Since oxygen-derived free radicals are able to inactivate NO [274,400], these results do
not exclude the possibility that antioxidants may regulate endothelial function in type 2 diabetes.
Administration of vitamin C [401], vitamin E [402], or Ubiqunol-10 [403] has improved
endothelial function in type 2 diabetic patients.
6.4 LDL oxidation and antioxidant capacity in different phenotypes of FCHL patients    
Growing evidence suggests that oxidizability of LDL is modified by dyslipidemias. Increased
susceptibility of LDL to oxidation in vitro has been reported in patients with
hypertriglyceridemia [404] and in some [405,406], but not all [407], studies in patients with
hypercholesterolemia. In patients with combined hyperlipidemia, small dense LDL subspecies
are less resistant to oxidation in vitro than is the buoyant LDL [408,409]. In Studies III and IV,
we found that the lag time for LDL oxidation in vitro was reduced in the combined group of all
FCHL patients (Figure 6B) and also in different FCHL phenotypes (Table 9) as compared to the
non-affected or healthy subjects. These results suggest that the LDL particles from FCHL
patients, independently of their lipid phenotype, are more susceptible to in vitro oxidation.
However, both total diene formation and the propagation rate for LDL oxidation were
comparable among the FCHL patients with different phenotypes and their healthy spouse
controls (Table 9). Previous data on these parameters have given inconsistent results in
hyperlipidemic patients [406,408]. 
Circulating LDL is well protected against oxidative stress by a highly effective plasma
antioxidant defense mechanism. An increased generation of free radicals in leukocytes, as
reported for both hypercholesterolemic and hypertriglyceridemic patients, can disrupt this
balance [410,411]. In Studies III and IV, elevations of plasma α-tocopherol as well as increases
in plasma uric acid, TRAPmea, and TRAPcalc in FCHL patients (Table 9) may represent an
adaptive response [412,413] to withstand the oxidative stress in dyslipidemia. α-Tocopherol is
transported mainly by plasma lipoproteins [414]. In Studies III and IV, plasma concentrations of
α-tocopherol were positively correlated with plasma lipids and were significantly higher in
FCHL patients with different phenotypes than in their healthy spouse controls (Table 9). These
results are in agreement with those of previous studies [415,416]. Taken together, these data
suggest that the increased concentration of plasma α-tocopherol in hyperlipidemic patients
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seems to be an epiphenomenon due to an increase in α-tocopherol transport capacity in
lipoproteins. Uric acid is also a major plasma antioxidant that can trap peroxyl radicals in its
aqueous phase [417]. In Study III, elevated plasma uric acid in FCHL patients with phenotypes
IIB and IV (Table 9) rises the antioxidant capacity, but the effect is insufficient in vivo [418].
The strong correlation between plasma TRAPmea and plasma α-tocopherol and uric acid in the
group of all FCHL family members indicated that plasma α-tocopherol and uric acid are the
major contributors to antioxidant capacity in FCHL. On the other hand, plasma concentrations of
vitamin C, protein-bound thiol groups, β-carotene, and retinol in different groups were
comparable (Table 9). 
The physical and chemical characteristics of LDL, such as LDL particle size [93], lipid or fatty
acid (PUFAs) content [116], and LDL endogenous antioxidants in LDL [117,118], are important
intrinsic factors that influence LDL oxidation in vitro. α-Tocopherol, the major lipid-soluble
antioxidant in LDL, accounts for approximately 80% of the antioxidant capacity of LDL
[419,420]. In Studies III and IV, the contents of lipid-soluble antioxidants (α-tocopherol, β-
carotene, and retinol) in LDL were comparable among FCHL patients, nonaffected FCHL family
members and their healthy spouse controls. These data are consistent with previous studies
[406,408]. Moreover, De Rijke et al found no difference in absolute and relative concentrations
of ubiquinol-10 in plasma and LDL between FCHL patients and their normolipidemic relatives
[408]. Alterations in these lipid-soluble antioxidants in LDL cannot, therefore, explain the
increased susceptibility of LDL to oxidation in vitro in FCHL patients.
Recent studies suggest that small dense LDL is an inherent feature of FCHL [291,313,314]. In
Studies III and IV, LDL peak particle diameter in FCHL patients was significantly smaller than
in their non-affected relatives and in their healthy spouse controls. LDL peak particle diameter
tended to be smaller in each affected group, particularly in the patients with IIB and IV
phenotypes (Study III). As expected, LDL peak particle diameter correlated negatively with
plasma TG and apoB, which is consistent with the observation that elevated levels of both
plasma TG and apoB are associated with the predominance of small dense LDL particles in
FCHL [297,313]. In addition, some studies have shown that LDL particles were also smaller in
phenotype IIA FCHL patients than in their non-affected relatives [291,297,314]. Hokanson et al
reported that in FCHL patients lowering of plasma TG by gemfibrozil had no effect on LDL
particle size [299]. These data suggest that there is a familial contribution to LDL size in FCHL
families [291,313,314], which is not explained by plasma TG levels. Overall, serum lipid and
lipoprotein concentration can explain approximately 60% of the variation of LDL particle profile
[291]. Segregation analysis has suggested that the small dense LDL trait in FCHL is determined
by a major gene and an additional polygenic component [291,312]. Consequently, the
predominance of small dense LDL in FCHL seems to be determined by both the genetic and the
lipid abnormalities in this population [291,313,316]. The fact that LDL size was similar in non-
affected subjects and their healthy spouse controls (Study III) does not exclude the possibility
that the non-affected subjects may become affected at an older age.
In Study III, LDL in FCHL patients was enriched in TG, particularly in those patients with IIB
and IV phenotypes. The inverse correlation between LDL peak particle diameter and TG content
of LDL in the group of all FCHL family members indicates that LDL size is linked to the
changes in LDL composition. These results are in agreement with previous studies [421,422]. In
FCHL, the enlarged pool size of apoB-containing triglyceride-rich particles, particularly VLDL
[297,313], together with a prolonged residence time of VLDL particles in circulation [71], may
favor the exchange of TG and CE between VLDL and LDL by CETP. This exchange of neutral
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lipids results in TG enrichment of LDL particles. Thereafter, HL remodels the TG-enriched LDL
by hydrolysis of TG in the core and phospholipids on the surface to convert them to small dense
particles [21,66,68]. Recently, Vakkilainen et al reported that, after adjustment for serum TG in
FCHL, HL and CETP activities are associated with LDL size [316]. 
In Studies III and IV, susceptibility of LDL to oxidation in vitro correlated positively with LDL
peak particle diameter and negatively with plasma TC, TG, and apoB concentrations in FCHL.
In the multivariate regression analysis in Study IV, LDL peak particle diameter, TC, and α-
tocopherol in LDL were independent determinants of lag time for LDL oxidation. The lipid-
soluble antioxidants, including α-tocopherol, in LDL among FCHL patients and their controls
were comparable. These results suggest that although α-tocopherol is the most abundant
antioxidant in LDL, it alone may be insufficient to prevent LDL oxidation [423]. Moreover, LDL
peak particle diameter in FCHL patients was smaller than in the non-affected FCHL family
members (Figure 6B) or in their healthy spouse controls (Study III). In FCHL patients, therefore,
the predominance of small dense LDL seems to be more important for the increased
susceptibility of LDL to oxidation in vitro than are the antioxidants in LDL. These results are
consistent with previous data [92,93,408]. 
6.5 LDL particle size and LDL oxidation and their relationship with carotid IMT in FCHL
Numerous studies have shown the association between LDL particle size and risk for CAD
[8,24]. Recently, LDL particle size has been associated with carotid IMT in middle-aged healthy
subjects in two studies [351,352]. However, LDL particle size was not associated with carotid
IMT in the patients with hypercholesterolemia [353,354] or with CAD risk among elderly
subjects [424] who had a relatively large LDL particle size or a relatively lower prevalence of
LDL phenotype B. In our asymptomatic FCHL cohort, characterized by a predominance of small
dense LDL, LDL particle size correlated significantly with mean IMT even after adjustment for
family number, age, BMI, and gender. More importantly, in multivariate analysis, the association
between LDL peak particle diameter and carotid mean IMT in FCHL was significant. These
results indicate that in FCHL LDL particle size may be related to the early development of
atherosclerosis. 
Oxidative modification of LDL is believed to play an important role in the development of
atherosclerosis [5]. Available studies on the relationship between atherosclerotic disease and
circulating oxidized LDL or autoantibodies against oxidized-LDL, however, have given
inconsistent results [136,355,356]. So far, few studies have investigated the association between
LDL oxidizability and the extent of arterial atherosclerosis. Susceptibility of LDL to oxidation
has been reported to be associated with CAD in a small-scale study [10] and with progression of
carotid atherosclerosis in a 3-year follow-up study [358], as well as in a group of children with
type 1 diabetes [359]. In contrast, LDL oxidizability was not associated with carotid
atherosclerosis [356,360] or was only marginally associated with the extent of coronary [11] or
peripheral [376] atherosclerosis. In our Study IV, lag time for LDL oxidation correlated with
carotid mean IMT in the univarite analysis, but in the multivarite regression analysis (Table 9)
this association disappeared. The differences in the stages of atherosclerosis and study designs
may account for these inconsistent results. Moreover, assessment of LDL oxidation in vitro is
problematic [377], and the method may affect the findings. Unfortunately, in previous studies,
LDL particle size was not measured. 
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Small dense LDL particles have been postulated to be atherogenic through several different
mechanisms. First, small dense LDL particles penetrate easily into the extracellular space
[21,66] and become trapped or retained by binding to arterial proteoglycans [22]. This process
promotes LDL modification in the arterial wall [22]. Consequently, small LDL particles become
even more susceptible to oxidation in the pro-oxidative environment of the subendothelial space.
In addition, small dense LDL also has a low binding affinity to LDL receptor and has reduced
hepatic clearance [21], resulting in a prolongation of its residence time in the subendothelial
space. Modified LDL is able to initiate several other processes that may further enhance the
development of atherosclerosis [5]. Thus, the size of LDL particles in FCHL may play a crucial
role in LDL oxidation and consequently in the atherosclerotic process. In our Study IV, it is not,
therefore, surprising that the susceptibility of LDL to oxidation in vitro is not an independent
risk factor for atherosclerosis in FCHL but is overshadowed by LDL particle size. However, both
measurements may reflect to some extent comparable alterations in LDL particles. 
6.6 Associations between HDL oxidation parameters and paraoxonase-1 and paraoxonase-
1 gene polymorphism in FCHL family members
In Study V, serum activities, mass concentrations, and specific activities of the PON1 between
the affected and non-affected FCHL family members were comparable. However, the relative
ratios of ARE/HDL and PON1 mass/HDL were significantly higher in affected family members
than in the non-affected. These results imply that there are higher ARE activities and more
PON1 mass available per unit weight of HDL-C in affected FCHL family members than in the
non-affected. These data, together with the observation that plasma TRAP and concentrations of
α-tocopherol and uric acid in affected FCHL patients were increased, may reflect an adaptive
response in FCHL [412,413] to withstand the enhanced generation of free radicals in leukocytes
in dyslipidemia [410,411]. In addition, in the combined data from Studies IV and V, we found a
positive correlation between plasma α–tocopherol concentrations and PON1 mass concentrations
and between the α–tocopherol and log PON1 activity; as well as between plasma retinol
concentrations and log ARE activity. Therefore, in FCHL patients, the increase in ARE/PON1
activities or in PON1 mass may also be explained by their increased antioxidant capacity (Table
9). Antioxidants may protect PON1 from inactivation by oxidized LDL [425].      
Some studies have shown that several HDL-associated enzymes: PON1, PON3, and PAF-AH, as
well as LCAT, may protect LDL from oxidation by inactivating oxidized phospholipids
[44,114,121]. Whether these enzymes, located on the HDL, may also protect HDL from
oxidation is unclear. Recently, the protective role of PON1 in HDL oxidation had been observed
in an experimental study [188], but data from a small-scale clinical study with type 2 diabetic
patients were negative [426]. In our Study V, correlations between parameters of HDL oxidation
and PON1 mass concentrations were significant in univariate analysis, and became even stronger
in multivariate analysis. These results indicate that the protective effect of PON1 on HDL
oxidation in vitro is independent of other lipid variables. These results were particularly evident
for maximal diene formation and propagation rate, but not for the lag phase. Studies have
reported that PON1 delayed the lag phase [188] when exogenous PON1 was added to the HDL.
Under our experimental conditions, the endogenous antioxidants (such as vitamins) of HDL may
be of greater importance for maintaining the lag phase. Because PON1 has the ability to
hydrolyze the newly formed oxidized phospholipids, it may be more functional in slowing down
the propagation rate and in reducing the amount of the conjugated diene formation. These data,
together with previous reports [164,427,428], suggest that PON1 mass concentration, but not its
activities, is related to its antioxidant action. Notably, PON1 contains only 1 free sulfhydryl
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group at Cys-284, which is required for the PON1 active site for protection of LDL against
oxidation [164,185,425,429]. Therefore the more PON1 mass available in HDL, the higher the
lipid peroxide-hydrolysing capacity by the enzyme. 
We observed a tendency in affected family members for the maximal diene formation and
propagation rate to be reduced. As a constant amount of HDL is used in in vitro studies, a greater
amount of PON1 was present for the HDL from affected family members, due to their higher
PON1/HDL ratio. These data, together with the significant correlations between PON1
mass/HDL-C and maximal dienes and propagation rate (Figure 8), indicate that the amount of
PON1 per unit mass of HDL may also be important in defining the protective effect of PON1 on
HDL. Further studies are necessary to confirm this. 
In Study V, PON1 genotypes 192QR and 55LM correlated with the three parameters of HDL
oxidation in vitro (Table 11). In the multivariate analysis (Table 11), the associations between
PON1 genotypes and oxidation parameters were insignificant, except for the association between
Q192R polymorphism and lag time (with HDL-C included in the analyses, Table 4) and maximal
diene formation (with apoAI included in the model, not shown). These results indicate that
PON1 gene polymorphism also modulates the antioxidant action of PON1 [162], although its
effect is weaker than that of the PON1 mass. Some published data have shown divergent
protective characteristics between PON1 Q and PON1 R allozymes [162-164]. These differences
may be due to the different affinities or preferences for the lipid peroxides as suggested by
Aviram et al [164], and therefore may contribute in different ways to protecting lipoproteins
from oxidation. This may also explain the association between PON1 192QR polymorphism and
CAD [168]. In addition, the PON1 55LM polymorphism has been linked with the CAD in
certain, but not in all studies [151]. Although the different antioxidant capacities of the PON1-
LL and PON1-MM allozymes were reported by Mackness et al [162], the multivariate analyses
indicate that the influence of PON1 55LM genotype on the antioxidant capacity of PON1 is
weaker than that of the PON1 192QR genotype. 
Study V indicates that the enzyme PON1 may exert protective effects at different stages of HDL
oxidation in vitro. PON1 mass was important for the antioxidant capacity of the enzyme. The
protective capacity of PON1 in HDL oxidation may be influenced by the PON1 gene
polymorphisms. Furthermore, our results, together with others’ [164,178], indicate that the
measurements of PON1 genotypes, PON1 and/or ARE activities, and PON1 mass
concentrations, particularly the latter, are important in studying the antioxidant capacity or
antiathergenic function of this HDL-associated enzyme. 
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7. SUMMARY AND CONCLUSIONS 
The findings and conclusions of original studies I to V can be summarized as follows:
1). A single bout of aerobic endurance exercise increased plasma TRAP, and concentrations of
uric acid and certain unknown circulating antioxidants as well as increasing the
susceptibility of LDL to oxidation in vitro. LDL peak particle diameter and lipid-soluble
antioxidant in LDL remained unchanged after the exercise. The increased circulating
antioxidants and antioxidant capacity can be viewed as an adaptive response to withstand
the increased load of newly generated free radicals during the marathon run. However, the
adaptive defense was insufficient to overcome the challenge of oxidative stress and caused a
shift in pro-oxidant/anti-oxidant balance in favor of the former. The increased oxidative
stress and unchanged antioxidant content in LDL may in part explain the unexpected
increase in the susceptibility of LDL to oxidation in vitro after the acute intensive exercise.
In addition, our data also showed that acute aerobic endurance exercise may increase
susceptibility of LDL to oxidation in vitro, and this may be harmful for the health of the
runner.
2). Patients with type 2 diabetes had a defect in endothelium-dependent vasodilation and a
smaller LDL peak particle diameter than did the healthy control subjects. The susceptibility
of LDL to oxidation in vitro, plasma antioxidants, and antioxidant capacity were, however,
comparable to those in nondiabetic subjects. LDL peak particle diameter—but not the lag
time for LDL oxidation, levels of plasma antioxidants, or LDL cholesterol—correlated with
the defect in endothelium-dependent vasodilation in type 2 diabetes. Decreased LDL particle
size therefore seems to be an important determinant of the impaired endothelium-dependent
vasodilation, an early sign of vascular injury in type 2 diabetes. 
3). The lag time for LDL oxidation was significantly shorter in FCHL patients with different
lipid phenotypes than in healthy spouse controls. LDL peak particle diameter in the
combined group of FCHL patients was smaller than in healthy spouse controls. Plasma
TRAP, uric acid, and α-tocopherol concentrations tended to be higher in affected FCHL
groups, especially in patients with phenotype IIB. The increase in plasma TRAP and
antioxidants may be an adaptation to withstand the increase in free radical production in
dyslipidemia. The decreased LDL particle size, but not the defect in antioxidant capacity,
may at least in part explain the increased susceptibility of LDL to oxidation in vitro in
FCHL.
4). LDL peak particle diameter and lag time for LDL oxidation were reduced in FCHL patients
as compared to their normolipidemic relatives. The carotid mean IMT was, however,
comparable between the two groups. Although LDL peak particle diameter and lag time for
LDL oxidation both were correlated with carotid mean IMT in univariate analysis, only
LDL peak particle diameter remained associated with carotid mean IMT in multivariate
analysis. These data demonstrate that LDL particle size, but not lag time for LDL oxidation,
may be an independent determinant of carotid mean IMT. The data also suggest that LDL
particle size seems to be important in the development of atherosclerosis in asymptomatic
FCHL family members. 
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5). PON1 mass significantly correlated with maximal dienes and propagation rate, but not with
lag time of the HDL oxidation in vitro in the univariate analyses. The oxidation parameters
also correlated with PON1 genotypes. In multivariate analyses, associations between PON1
mass and oxidation parameters were independent of other factors, including HDL-
cholesterol and apoAI. PON1 may therefore have protective effects on in vitro HDL
oxidation in FCHL family members. The presence of PON1 mass in HDL seems to be one
important factor when evaluating the anti-atherogenic function of HDL. 
In conclusion, the present studies demonstrate that LDL particle size seems to be a more
important factor in the development of preclinical atherosclerosis than is the susceptibility of
LDL to oxidation in vitro in type 2 diabetes and in FCHL subjects free of cardiovascular disease.
The presence of small-size LDL particles usually means that the number of circulating LDL
particles is increased more than is indicated by LDL-cholesterol levels. Consequently, the
number of LDL particles seems to be more closely related to CAD risk than are levels of LDL
cholesterol [26,430]. One may extrapolate that ”the number of LDL particles” is more important
than is the ”oxidative susceptibility of LDL” in the development of early atherosclerosis. Given
that atherosclerosis is a disorder of lipid accumulation, the elevated “number” or “level” of LDL
cholesterol seems to be the key risk factor for atherosclerosis [26], although LDL oxidation may
occur in vivo [5,431]. Several recent large-scale clinical trials have shown that lipid lowering,
but not the antioxidant administration, can significantly reduce the mortality or incidence of
vascular diseases in high-risk individuals [1-3,18,20]. In some clinical studies, the reduction in
small dense LDL with lipid-lowering drugs may reduce coronary artery stenosis [25,100]. 
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